

Updated European Heart Rhythm Association Practical antagonist anticoagulants in patients with non-valvular

Europace

17, 1467-1507

DOI: [10.1093/europace/euv309](https://doi.org/10.1093/europace/euv309)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Alzheimer's disease: the impact of age-related changes in reproductive hormones. Cellular and Molecular Life Sciences, 2005, 62, 281-292.	2.4	41
2	Compensatory caspase activation in MPP ⁺ -induced cell death in dopaminergic neurons. Cellular and Molecular Life Sciences, 2005, 62, 227-238.	2.4	23
3	Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach. BMC Cardiovascular Disorders, 2015, 15, 143.	0.7	56
4	Stroke prevention in atrial fibrillation: Where are we now?. Indian Heart Journal, 2015, 67, S1-S3.	0.2	1
5	Anti-coagulation for Patients with Acute Coronary Syndrome. Journal of the Japanese Coronary Association, 2015, 21, 272-277.	0.0	0
6	Management of Antithrombotic Agents in Oral Surgery Maria Martinez and Dimitrios A. Tsakiris *. Dentistry Journal, 2015, 3, 93-101.	0.9	6
7	Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management—a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis. European Heart Journal, 2017, 38, ehv676.	1.0	48
8	Management of atrial fibrillation in patients with chronic kidney disease in Europe Results of the European Heart Rhythm Association Survey. Europace, 2015, 17, 1862-1867.	0.7	24
9	Current and developing strategies for monitoring and reversing direct oral anticoagulants in patients with non-valvular atrial fibrillation. Hospital Practice (1995), 2015, 43, 258-267.	0.5	3
10	The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants. Indian Heart Journal, 2015, 67, S13-S34.	0.2	11
11	Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease. Rational Pharmacotherapy in Cardiology, 2016, 12, 595-602.	0.3	3
12	Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true. Rational Pharmacotherapy in Cardiology, 2016, 12, 465-470.	0.3	1
13	New Oral Anticoagulants: General Features and Review of Pivotal Clinical Trials. The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2016, 16, 178.	0.1	1
14	Interaction of rivaroxaban with amiodarone, verapamil and diltiazem in patients with atrial fibrillation: terra incognita. Rational Pharmacotherapy in Cardiology, 2016, 12, 101-105.	0.3	0
15	Effective management of venous thromboembolism in the community: non-vitamin K antagonist oral anticoagulants. International Journal of General Medicine, 2016, 9, 107.	0.8	4
16	Dabigatran approaching the realm of heparin-induced thrombocytopenia. Blood Research, 2016, 51, 77.	0.5	8
17	Medication Error When Switching from Warfarin to Rivaroxaban Leading to Spontaneous Large Ecchymosis of the Abdominal and Chest Wall. Clinics and Practice, 2016, 6, 57-60.	0.6	5
18	Individualising Anticoagulant Therapy in Atrial Fibrillation Patients. Arrhythmia and Electrophysiology Review, 2016, 5, 102.	1.3	5

#	ARTICLE	IF	CITATIONS
19	Direct Oral Anticoagulants in Emergency Trauma Admissions. <i>Deutsches Arzteblatt International</i> , 2016, 113, 575-82.	0.6	35
20	Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran. <i>Drug Design, Development and Therapy</i> , 2016, 10, 1683.	2.0	9
21	New Direct Oral Anticoagulants (DOAC) and Their Use Today. <i>Dentistry Journal</i> , 2016, 4, 5.	0.9	36
22	Risk of myocardial infarction and death in patients with atrial fibrillation treated with dabigatran or vitamin K antagonists. <i>Thrombosis and Haemostasis</i> , 2016, 116, 1150-1158.	1.8	8
23	Minimizing bleeding risk in patients receiving direct oral anticoagulants for stroke prevention. <i>International Journal of General Medicine</i> , 2016, Volume 9, 337-347.	0.8	12
24	Pulmonary embolism: new treatments for an old problem. <i>Open Access Emergency Medicine</i> , 2016, Volume 8, 87-95.	0.6	2
25	Antithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulation. <i>Postępy W Kardiologii Interwencyjnej</i> , 2016, 4, 290-302.	0.1	3
26	The Influence of Assay Selection on Prothrombin Time Measured in Patients Treated With Rivaroxaban for Nonvalvular Atrial Fibrillation. <i>Journal of Clinical Laboratory Analysis</i> , 2016, 30, 941-946.	0.9	7
27	Deep vein thrombosis and pulmonary embolism. <i>Lancet, The</i> , 2016, 388, 3060-3073.	6.3	572
28	Management of direct oral anticoagulants-associated bleeding in the trauma patient. <i>Current Opinion in Anaesthesiology</i> , 2016, 29, 220-228.	0.9	16
29	Idarucizumab: A Review as a Reversal Agent for Dabigatran. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 297-304.	1.0	12
30	Therapeutic Review of Methylprednisolone Acetate Intra-articular Injection in the Management of Osteoarthritis of the Knee – Part 2: Clinical and Procedural Considerations. <i>Musculoskeletal Care</i> , 2016, 14, 252-266.	0.6	7
31	Sixteen-year nationwide trends in antithrombotic drug use in Denmark and its correlation with landmark studies. <i>Heart</i> , 2016, 102, 1883-1889.	1.2	45
32	What do the guidelines suggest for non-vitamin K antagonist oral anticoagulant use for stroke prevention in atrial fibrillation?. <i>European Heart Journal Supplements</i> , 2016, 18, I18-I24.	0.0	2
34	Glomerular filtration rate in patients with atrial fibrillation and 1-year outcomes. <i>Scientific Reports</i> , 2016, 6, 30271.	1.6	51
35	Direct new oral anticoagulants: follow-up, guidelines and bleeding complications in general practice—a survey of Swiss general internal medicine practitioners. <i>SpringerPlus</i> , 2016, 5, 2030.	1.2	12
36	Non-Vitamin K Anticoagulant Dose Selection. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2605-2607.	1.2	2
37	2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 893-952.	0.8	113

#	ARTICLE	IF	CITATIONS
38	Gastrointestinal bleeding secondary to the new anticoagulants. <i>Current Opinion in Gastroenterology</i> , 2016, 32, 474-480.	1.0	11
39	Postoperative bleeding and coagulation disorders. <i>Current Opinion in Critical Care</i> , 2016, 22, 365-369.	1.6	4
40	The year in cardiology 2015: arrhythmias and device therapy. <i>Egyptian Heart Journal</i> , 2016, 68, 311-317.	0.4	0
41	The role of the new oral anticoagulants in the treatment of coronary disease. <i>Revista Colombiana De Cardiologia</i> , 2016, 23, e13-e15.	0.1	0
43	Perioperative management of antithrombotic treatment during implantation or revision of cardiac implantable electronic devices: the European Snapshot Survey on Procedural Routines for Electronic Device Implantation (ESS-PREDI). <i>Europace</i> , 2016, 18, 778-784.	0.7	19
44	Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AFâ€“TIMI 48 Trial. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	215
45	Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 671-679.	0.8	26
46	â€“Real-worldâ€™ atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase. <i>Europace</i> , 2016, 19, euw112.	0.7	55
48	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2016, 37, 2129-2200.	1.0	13,008
49	The Role of Nonvitamin K Antagonist Oral Anticoagulants (NOACs) in Stroke Prevention in Patients with Atrial Fibrillation. <i>Current Neurology and Neuroscience Reports</i> , 2016, 16, 47.	2.0	3
51	Treatment of Venous Thromboembolism With New Anticoagulant Agents. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1941-1955.	1.2	63
52	Once-daily rivaroxaban for long-term stroke prevention in patients with atrial fibrillation. <i>European Heart Journal Supplements</i> , 2016, 18, D7-D15.	0.0	2
53	Overview of direct oral anticoagulant therapy reversal. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, s5-s13.	0.5	13
54	Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. <i>Critical Care</i> , 2016, 20, 115.	2.5	40
55	Benefits of once-daily dosing with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>European Heart Journal Supplements</i> , 2016, 18, D1-D6.	0.0	7
56	Evolving Treatments for Arterial and Venous Thrombosis. <i>Circulation Research</i> , 2016, 118, 1409-1424.	2.0	96
57	Quick reference guide to the new oral anticoagulants. <i>Journal of Vascular Surgery</i> , 2016, 63, 1653-1657.	0.6	6
59	Use of direct oral anticoagulants with regional anesthesia in orthopedic patients. <i>Journal of Clinical Anesthesia</i> , 2016, 32, 224-235.	0.7	14

#	ARTICLE	IF	CITATIONS
60	Reversal of dabigatran by idarucizumab: when and how?. Expert Review of Hematology, 2016, 9, 519-528.	1.0	5
61	Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience. American Journal of Medicine, 2016, 129, S33-S40.	0.6	74
62	Evidence Supporting Idarucizumab for the Reversal of Dabigatran. American Journal of Medicine, 2016, 129, S73-S79.	0.6	12
63	Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols. American Journal of Medicine, 2016, 129, S89-S96.	0.6	12
64	2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology, 2016, 32, 1170-1185.	0.8	243
65	New Oral Anticoagulants in Nonvalvular Atrial Fibrillation. Clinical Cardiology, 2016, 39, 739-746.	0.7	15
66	Administration of Coagulation-Altering Therapy in the Patient Presenting for Oral Health and Maxillofacial Surgery. Oral and Maxillofacial Surgery Clinics of North America, 2016, 28, 443-460.	0.4	2
67	Management issues of chronic therapy with non-vitamin K oral anticoagulants or antiplatelet agents: Different or alike?. International Journal of Cardiology, 2016, 221, 695-696.	0.8	2
68	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Journal of Cardio-thoracic Surgery, 2016, 50, e1-e88.	0.6	754
69	Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation. Hematology/Oncology Clinics of North America, 2016, 30, 1019-1034.	0.9	9
70	Evidence supporting idarucizumab for the reversal of dabigatran. American Journal of Emergency Medicine, 2016, 34, 33-38.	0.7	11
71	Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols. American Journal of Emergency Medicine, 2016, 34, 46-51.	0.7	16
72	Perioperative management of anticoagulation and antiplatelet therapy. British Journal of Haematology, 2016, 175, 602-613.	1.2	159
73	Re-initiation of dabigatran and direct factor Xa antagonists after a major bleed. American Journal of Emergency Medicine, 2016, 34, 19-25.	0.7	3
74	Anti-Xa bioassays for the laboratory measurement of direct Factor Xa inhibitors in plasma, in selected patients. Transfusion and Apheresis Science, 2016, 55, 249-261.	0.5	4
75	Risk-Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies. Drug Safety, 2016, 39, 1175-1187.	1.4	31
76	Bleeding with direct oral anticoagulants vs warfarin: clinical experience. American Journal of Emergency Medicine, 2016, 34, 3-8.	0.7	25
77	Place of non-vitamin K antagonist oral anticoagulants in anticoagulant-antiplatelet combinations in peripheral artery disease. Archives of Cardiovascular Diseases, 2016, 109, 634-640.	0.7	1

#	ARTICLE	IF	CITATIONS
78	30-year nationwide trends in incidence of atrial fibrillation in Denmark and associated 5-year risk of heart failure, stroke, and death. <i>International Journal of Cardiology</i> , 2016, 225, 30-36.	0.8	45
79	Direct oral anticoagulants: unique properties and practical approaches to management. <i>Heart</i> , 2016, 102, 1620-1626.	1.2	16
81	Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2033-2047.	0.9	4
82	Non-vitamin K oral anticoagulant treatment in elderly patients with atrial fibrillation and coronary heart disease. <i>International Journal of Cardiology</i> , 2016, 222, 1079-1083.	0.8	10
83	Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease. <i>Circulation</i> , 2016, 134, 589-598.	1.6	140
84	Risk stratification, perioperative and periprocedural management of the patient receiving anticoagulant therapy. <i>Journal of Clinical Anesthesia</i> , 2016, 34, 586-599.	0.7	19
85	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 891-975.	2.9	5,272
86	Novel oral anticoagulant management issues for the stroke clinician. <i>International Journal of Stroke</i> , 2016, 11, 759-767.	2.9	4
87	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Heart Journal</i> , 2016, 37, 2893-2962.	1.0	5,689
88	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>Europace</i> , 2016, 18, 1609-1678.	0.7	3,523
89	Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed. <i>American Journal of Medicine</i> , 2016, 129, S54-S63.	0.6	9
90	Risk Stratification for Recurrence and Mortality in Embolic Stroke of Undetermined Source. <i>Stroke</i> , 2016, 47, 2278-2285.	1.0	69
91	Anticoagulation After Heart Valve Replacement or Transcatheter Valve Implantation. <i>American Journal of Cardiology</i> , 2016, 118, 1419-1426.	0.7	12
92	Major bleeding complications in patients treated with direct oral anticoagulants: One-year observational study in a Paris Hospital. <i>Current Research in Translational Medicine</i> , 2016, 64, 129-133.	1.2	2
93	Introduction to Direct Oral Anticoagulants and Rationale for Specific Reversal Agents. <i>American Journal of Medicine</i> , 2016, 129, S31-S32.	0.6	2
94	Drug-drug interactions of non-vitamin K oral anticoagulants. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1445-1461.	1.5	36
95	Efficacy and Safety of Rivaroxaban and Warfarin in the Perioperative Period of Catheter Ablation for Atrial Fibrillation—Outcome Analysis From a Prospective Multicenter Registry Study in Japan. <i>Circulation Journal</i> , 2016, 80, 2295-2301.	0.7	28
97	Knowledge gaps in patients with atrial fibrillation revealed by a new validated knowledge questionnaire. <i>International Journal of Cardiology</i> , 2016, 223, 906-914.	0.8	65

#	ARTICLE	IF	CITATIONS
98	Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment. <i>European Journal of Heart Failure</i> , 2016, 18, 1162-1171.	2.9	26
99	Prevention of Gastrointestinal Bleeding in Patients Receiving Direct Oral Anticoagulants. <i>American Journal of Gastroenterology Supplements (Print)</i> , 2016, 3, 2-12.	0.7	12
100	Measuring non-vitamin K antagonist oral anticoagulant levels: When is it appropriate and which methods should be used?. <i>International Journal of Stroke</i> , 2016, 11, 748-758.	2.9	46
101	Safety and Feasibility of Treatment with Rivaroxaban for Non-Canonical Indications: A Case Series Analysis. <i>Clinical Drug Investigation</i> , 2016, 36, 857-862.	1.1	7
102	Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents. <i>Circulation</i> , 2016, 134, 248-261.	1.6	98
103	Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2016, 134, 24-36.	1.6	234
104	Introduction to direct oral anticoagulants and rationale for specific reversal agents. <i>American Journal of Emergency Medicine</i> , 2016, 34, 1-2.	0.7	8
106	DOACs – advances and limitations in real world. <i>Thrombosis Journal</i> , 2016, 14, 17.	0.9	69
107	Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2017, 38, ehw454.	1.0	86
108	Reversal of direct oral anticoagulants in hemophilia treatment. <i>Memo - Magazine of European Medical Oncology</i> , 2016, 9, 131-135.	0.3	2
110	Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing oral or dental procedures. <i>The Cochrane Library</i> , 2016, , .	1.5	2
111	Stroke prevention strategies in patients with atrial fibrillation and heart valve abnormalities: perceptions of “valvular” atrial fibrillation: results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2016, 18, 1593-1598.	0.7	13
112	Prolonged anticoagulation in VTE with direct oral anticoagulants: towards an individual analysis of net clinical benefit?. <i>European Respiratory Journal</i> , 2016, 48, 1268-1270.	3.1	0
113	Assessment and Management of Gastrointestinal Hemorrhage in the Setting of Direct Oral Anticoagulants: The Hematology Perspective. <i>American Journal of Gastroenterology Supplements (Print)</i> , 2016, 3, 29-35.	0.7	2
114	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	83
115	Clinical events preceding switching and discontinuation of oral anticoagulant treatment in patients with atrial fibrillation. <i>Europace</i> , 2017, 19, euw241.	0.7	29
116	Health benefits of hosting major international events. <i>Cmaj</i> , 2016, 188, 369.2-369.	0.9	1
117	Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2016, 116, 747-753.	1.8	28

#	ARTICLE	IF	CITATIONS
118	Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. <i>BMJ</i> , The, 2016, 353, i3189.	3.0	351
119	Risk of Direct Oral Anticoagulant Bioaccumulation in Patients with Pulmonary Hypertension. <i>Respiration</i> , 2016, 91, 307-315.	1.2	18
120	Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2016, 116, 410-416.	1.8	39
122	Sequential Hybrid CryoMaze Ablation versus Surgical CryoMaze Alone for the Treatment of Atrial Fibrillation (SurHyb): study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 518.	0.7	2
124	Catheter ablation for atrial flutter: a survey by the European Heart Rhythm Association and Canadian Heart Rhythm Society. <i>Europace</i> , 2016, 18, 1880-1885.	0.7	10
125	Intravenous Thrombolysis after Reversal of Dabigatran by Idarucizumab: A Case Report. <i>Case Reports in Neurology</i> , 2016, 8, 140-144.	0.3	31
126	Adherence to long-term anticoagulation treatment, what is known and what the future might hold. <i>British Journal of Haematology</i> , 2016, 174, 30-42.	1.2	55
127	Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. <i>European Heart Journal</i> , 2017, 38, ehw058.	1.0	203
128	Resuming anticoagulant therapy after intracerebral bleeding. <i>Vascular Pharmacology</i> , 2016, 84, 15-24.	1.0	17
129	Defining nonvalvular atrial fibrillation: A quest for clarification. <i>American Heart Journal</i> , 2016, 178, 161-167.	1.2	17
130	Evaluation of 5 Prognostic Scores for Prediction of Stroke, Thromboembolic and Coronary Events, All-Cause Mortality, and Major Adverse Cardiac Events in Patients With Atrial Fibrillation and Coronary Stenting. <i>American Journal of Cardiology</i> , 2016, 118, 700-707.	0.7	22
131	An update on laboratory measurements of Dabigatran: Smart specific and calibrated dedicated assays for measuring anti-IIa activity in plasma. <i>Transfusion and Apheresis Science</i> , 2016, 54, 428-437.	0.5	9
132	Decision-making around antithrombotics for stroke prevention in atrial fibrillation: the health professionals' views. <i>International Journal of Clinical Pharmacy</i> , 2016, 38, 985-995.	1.0	11
133	Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2888-2899.	1.2	171
135	Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time. <i>JAMA Cardiology</i> , 2016, 1, 451.	3.0	137
136	Non-vitamin K oral anticoagulants in patients with atrial fibrillation after cardiac surgery: the results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2016, 18, 1113-1116.	0.7	12
137	Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 201-214.	1.3	18
138	Major Bleeding and Hemorrhagic Stroke With Direct Oral Anticoagulants in Patients With Renal Failure. <i>Chest</i> , 2016, 149, 1516-1524.	0.4	43

#	ARTICLE	IF	CITATIONS
139	The use of new anticoagulant drugs in ventricular assist devices: Another brick in the wall?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 151, e83-e84.	0.4	2
140	Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy. <i>International Journal of Cardiology</i> , 2016, 203, 372-378.	0.8	36
141	NOACs: drug-drug interactions. <i>Cmaj</i> , 2016, 188, 369.3-369.	0.9	0
142	How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation. <i>Annals of Hematology</i> , 2016, 95, 437-449.	0.8	56
143	Identifying skull fractures in young children. <i>Cmaj</i> , 2016, 188, 369.1-369.	0.9	0
144	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Summary of the document prepared by the Czech Society of Cardiology. <i>Cor Et Vasa</i> , 2016, 58, e153-e174.	0.1	5
145	Emerging Tools for Stroke Prevention in Atrial Fibrillation. <i>EBioMedicine</i> , 2016, 4, 26-39.	2.7	15
146	Targeting thrombin long-term after an acute coronary syndrome: Opportunities and challenges. <i>Vascular Pharmacology</i> , 2016, 81, 1-14.	1.0	8
148	Why switch from warfarin to NOACs?. <i>Internal and Emergency Medicine</i> , 2016, 11, 289-293.	1.0	35
149	Net clinical benefit of adding aspirin to warfarin in patients with atrial fibrillation: Insights from the J-RHYTHM Registry. <i>International Journal of Cardiology</i> , 2016, 212, 311-317.	0.8	8
151	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. <i>European Heart Journal</i> , 2016, 38, ehv643.	1.0	69
152	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. <i>European Heart Journal</i> , 2017, 38, ehw069.	1.0	106
153	Management of antithrombotic therapy during cardiac implantable device surgery. <i>Journal of Arrhythmia</i> , 2016, 32, 163-169.	0.5	19
154	Management of Venous Thromboembolism. <i>Annals of Pharmacotherapy</i> , 2016, 50, 486-501.	0.9	21
155	Atrial Fibrillation and Stroke. <i>Cardiology Clinics</i> , 2016, 34, 317-328.	0.9	7
156	Novel oral anticoagulants in plastic surgery. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2016, 69, 585-593.	0.5	8
157	The year in cardiology 2015: arrhythmias and device therapy. <i>European Heart Journal</i> , 2016, 37, 587-593.	1.0	0
158	Reversal Agents for the New Generation of Oral Anticoagulants: Implications for the Perioperative Physician. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2016, 30, 823-830.	0.6	11

#	ARTICLE	IF	CITATIONS
160	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2016, 18, 37-50.	0.7	121
161	Edoxaban in patients with atrial fibrillation. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2017, 11, 81-90.	1.0	4
162	Direct oral anticoagulants: Current indications and unmet needs in the treatment of venous thromboembolism. <i>Pharmacological Research</i> , 2017, 118, 33-42.	3.1	31
165	Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs). <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 343-351.	1.0	68
166	Antiplatelet therapies in patients with an indication for anticoagulation. <i>Clinical Hemorheology and Microcirculation</i> , 2017, 64, 273-278.	0.9	4
167	2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017, 69, 871-898.	1.2	342
168	Non-vitamin K antagonist oral anticoagulants and the management of bleeding. <i>Medicine</i> , 2017, 45, 139-143.	0.2	2
169	Switching, Adverse Effects and Use of Over-the-Counter Analgesics among Users of Oral Anticoagulants: A Pharmacy-based Survey. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 121, 37-43.	1.2	10
170	Management of acute upper GI bleeding. <i>BJA Education</i> , 2017, 17, 117-123.	0.6	3
171	Catheter ablation for atrial flutter: a survey by the European Heart Rhythm Association and Canadian Heart Rhythm Society. <i>Europace</i> , 2017, 19, e1-e1.	0.7	4
172	Relation of Stroke and Major Bleeding to Creatinine Clearance in Patients With Atrial Fibrillation (from the Fushimi AF Registry). <i>American Journal of Cardiology</i> , 2017, 119, 1229-1237.	0.7	36
174	Early use of direct oral anticoagulants after TIA/stroke in patients with atrial fibrillation: a 2016 update. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 302-305.	1.0	1
175	Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide. <i>Advances in Therapy</i> , 2017, 34, 620-637.	1.3	8
176	Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 306-317.	1.0	50
177	Clinical implications of reversal agents for direct oral anticoagulants. <i>Future Cardiology</i> , 2017, 13, 153-159.	0.5	7
179	The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. <i>Cancer Treatment Reviews</i> , 2017, 55, 71-82.	3.4	56
180	Reversing the anticoagulation effects of dabigatran. <i>Hospital Practice (1995)</i> , 2017, 45, 29-38.	0.5	13
181	Determinants of Heparin Dosing and Complications in Patients Undergoing Left Atrial Ablation on Uninterrupted Rivaroxaban. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2017, 40, 183-190.	0.5	9

#	ARTICLE	IF	CITATIONS
182	Cost Effectiveness of Genotype-Guided Warfarin Dosing in Patients with Mechanical Heart Valve Replacement Under the Fee-for-Service System. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 657-667.	1.0	17
183	Intravenous thrombolysis after reversal of dabigatran by idarucizumab: a moment to be a pioneer. <i>Acta Neurologica Belgica</i> , 2017, 117, 753-755.	0.5	15
184	Reply. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1212.	1.2	3
185	Italian intersociety consensus on DOAC use in internal medicine. <i>Internal and Emergency Medicine</i> , 2017, 12, 387-406.	1.0	44
186	Cutaneous Burn Injury Promotes Shifts in the Bacterial Microbiome in Autologous Donor Skin. <i>Shock</i> , 2017, 48, 441-448.	1.0	36
188	Non-Hemodynamic Effects of Catecholamines. <i>Shock</i> , 2017, 48, 390-400.	1.0	58
189	Minocycline Prevents the Impairment of Hippocampal Long-Term Potentiation in the Septic Mouse. <i>Shock</i> , 2017, 48, 209-214.	1.0	29
190	Management of Atrial Fibrillation with Rapid Ventricular Response in the Intensive Care Unit. <i>Shock</i> , 2017, 48, 436-440.	1.0	26
191	Triple antithrombotic therapy, including NAO, in patients after coronary stenting. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, e125-e128.	0.6	0
192	Protection by Inhaled Hydrogen Therapy in a Rat Model of Acute Lung Injury can be Tracked in vivo Using Molecular Imaging. <i>Shock</i> , 2017, 48, 467-476.	1.0	20
193	Management of Severe Bleeding in Patients Treated with Direct Oral Anticoagulants. <i>Anesthesiology</i> , 2017, 127, 111-120.	1.3	52
194	Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation. <i>Advances in Therapy</i> , 2017, 34, 1283-1290.	1.3	4
195	Evaluating adherence to non-vitamin-K antagonist oral anticoagulants in post-approval observational studies of patients with atrial fibrillation. <i>Current Medical Research and Opinion</i> , 2017, 33, 1175-1177.	0.9	3
196	Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation. <i>Thrombosis Research</i> , 2017, 155, 38-47.	0.8	27
197	Anticoagulation Bridge Therapy in Patients with Atrial Fibrillation: Recent Updates Providing a Rebalance of Risk and Benefit. <i>Pharmacotherapy</i> , 2017, 37, 712-724.	1.2	18
198	The Reversal of Direct Oral Anticoagulants in Animal Models. <i>Shock</i> , 2017, 48, 144-158.	1.0	5
199	International Normalized Ratio Is Significantly Elevated With Rivaroxaban and Apixaban Drug Therapies: A Retrospective Study. <i>Clinical Therapeutics</i> , 2017, 39, 1003-1010.	1.1	27
200	Dabigatran plasma levels, aPTT and thromboelastography in patients with AF: implications for allowing early non-elective surgical procedures. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 9-13.	1.0	8

#	ARTICLE	IF	CITATIONS
201	Appropriateness of Oral Anticoagulants for the Long-Term Treatment of Atrial Fibrillation in Older People: Results of an Evidence-Based Review and International Consensus Validation Process (OAC-FORTA 2016). <i>Drugs and Aging</i> , 2017, 34, 499-507.	1.3	43
203	Management of severe perioperative bleeding. <i>European Journal of Anaesthesiology</i> , 2017, 34, 332-395.	0.7	650
204	Dabigatran etexilate: appropriate use in patients with chronic kidney disease and in the elderly patients. <i>Internal and Emergency Medicine</i> , 2017, 12, 425-435.	1.0	6
205	Managing hip fracture and lower limb surgery in the emergency setting. <i>Journal of Trauma and Acute Care Surgery</i> , 2017, 82, 1112-1121.	1.1	10
206	Direct oral anticoagulants and digestive bleeding: therapeutic management and preventive measures. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 495-505.	1.4	25
207	Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 365-379.	1.0	89
208	Coagulation Testing in Acute Ischemic Stroke Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants. <i>Stroke</i> , 2017, 48, 152-158.	1.0	34
210	New frontiers in anticoagulation: non vitamin-K oral anticoagulants in stroke prevention. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 539-552.	1.4	2
211	Management of acute stroke in patients on oral anticoagulants. <i>Current Opinion in Neurology</i> , 2017, 30, 1-7.	1.8	15
212	Mechanisms Involved in Secondary Cardiac Dysfunction in Animal Models of Trauma and Hemorrhagic Shock. <i>Shock</i> , 2017, 48, 401-410.	1.0	18
213	Loss of Syndecan-1 Abrogates the Pulmonary Protective Phenotype Induced by Plasma After Hemorrhagic Shock. <i>Shock</i> , 2017, 48, 340-345.	1.0	42
214	Dabigatran in nonvalvular atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 467-477.	0.6	7
215	Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2779-2790.	1.2	398
216	Novel (Oral) Anticoagulant Challenges in Surgery. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 706-715.	1.5	5
218	Oral Anticoagulation Therapy. , 2017, , .		1
220	Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2017, 26, 2102-2110.	0.7	12
222	Perioperative management of patients on direct oral anticoagulants. <i>Thrombosis Journal</i> , 2017, 15, 14.	0.9	92
223	Extensive Bruising and Elevated Rivaroxaban Plasma Concentration in a Patient Receiving Cobicistat-Boosted Elvitegravir. <i>Annals of Pharmacotherapy</i> , 2017, 51, 713-714.	0.9	12

#	ARTICLE	IF	CITATIONS
224	Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany – A national case collection. <i>International Journal of Stroke</i> , 2017, 12, 383-391.	2.9	80
225	Emerging therapeutic uses of direct-acting oral anticoagulants: An evidence-based perspective. <i>Pharmacological Research</i> , 2017, 120, 206-218.	3.1	11
226	Direct acting oral anticoagulant: Bench to bedside. <i>Medical Journal Armed Forces India</i> , 2017, 73, 274-281.	0.3	0
227	Use of oral anticoagulation for patients who undergo invasive procedures. <i>Revista Clínica Española</i> , 2017, 217, 103-107.	0.3	1
229	Early secondary prevention after initially ineffective revascularization treatments for acute ischemic stroke due to tandem occlusion. <i>Blood Coagulation and Fibrinolysis</i> , 2017, 28, 493-495.	0.5	2
230	Ensuring adherence to therapy with anticoagulation in patients with atrial fibrillation. <i>Heart</i> , 2017, 103, 1308-1309.	1.2	10
231	Oral anticoagulant therapy for older patients with atrial fibrillation: a review of current evidence. <i>European Journal of Internal Medicine</i> , 2017, 41, 18-27.	1.0	26
232	Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2017, 2, 566.	3.0	106
233	Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: Suggested strategies tailored to an integrated evaluation of different risk profiles. <i>European Journal of Internal Medicine</i> , 2017, 41, e10-e11.	1.0	1
234	Cardiac Management in the Frail Elderly Patient and the Oldest Old. , 2017, , .		3
235	The role of new oral anticoagulants in orthopaedics: an update of recent evidence. <i>European Journal of Orthopaedic Surgery and Traumatology</i> , 2017, 27, 573-582.	0.6	12
236	Anticoagulation treatment. <i>Medicine</i> , 2017, 45, 239-243.	0.2	1
237	Rivaroxaban in patients with atrial fibrillation: from ROCKET AF to everyday practice. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 403-413.	0.6	11
238	Atrial Fibrillation on Vitamin K Antagonist Undergoing Primary Percutaneous Coronary Intervention for Acute ST-Elevation Myocardial Infarction. , 2017, , 79-94.		0
239	Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 42-47.	1.4	47
240	Direct oral anticoagulants and heparins: laboratory values and pitfalls in “bridging therapy”. <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 51, ezw368.	0.6	7
241	The Polyanalgesic Consensus Conference (PACC): Recommendations for Intrathecal Drug Delivery: Guidance for Improving Safety and Mitigating Risks. <i>Neuromodulation</i> , 2017, 20, 155-176.	0.4	121
242	Atrial Fibrillation on Vitamin K Antagonist Oral Anticoagulant Undergoing Urgent Percutaneous Coronary Intervention for Non-ST-Elevation Acute Coronary Syndrome. , 2017, , 59-77.		0

#	ARTICLE	IF	CITATIONS
243	Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 120, 407-410.	1.2	11
244	Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know. <i>Pharmacotherapy</i> , 2017, 37, 236-248.	1.2	97
245	Clinical conundrums in antithrombotic therapy management: A Delphi Consensus panel. <i>International Journal of Cardiology</i> , 2017, 249, 249-256.	0.8	12
247	2017 ESC/EACTS Guidelines for the management of valvular heart disease. <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 52, 616-664.	0.6	510
248	Hospital admissions for bleeding events associated with treatment with apixaban, dabigatran and rivaroxaban. <i>European Journal of Hospital Pharmacy</i> , 2017, 26, ejhpharm-2017-001390.	0.5	7
249	Pharmacological and Non-pharmacological Treatments for Stroke Prevention in Patients with Atrial Fibrillation. <i>Advances in Therapy</i> , 2017, 34, 2274-2294.	1.3	6
250	Anticoagulation: The Successes and Pitfalls of Long-Term Management. <i>Physician Assistant Clinics</i> , 2017, 2, 603-622.	0.1	0
251	2017 ESC/EACTS Guidelines for the management of valvular heart disease. <i>European Heart Journal</i> , 2017, 38, 2739-2791.	1.0	5,142
252	Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial. <i>Europace</i> , 2017, 19, 1630-1636.	0.7	16
253	“To bridge or not to bridge” Is it still the question?. <i>Medicina Clínica (English Edition)</i> , 2017, 149, 303-304.	0.1	0
254	Preliminary report: Measurement of apixaban and rivaroxaban in plasma from bleeding patients. <i>European Journal of Haematology</i> , 2017, 99, 431-436.	1.1	6
256	Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 2125-2137.	1.9	39
257	Mobile Health Technology for Atrial Fibrillation Management Integrating Decision Support, Education, and Patient Involvement: mAF App Trial. <i>American Journal of Medicine</i> , 2017, 130, 1388-1396.e6.	0.6	172
258	Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 527-535.	1.0	9
259	Rivaroxaban vs Warfarin Sodium in the Ultra-Early Period After Atrial Fibrillation-Related Mild Ischemic Stroke. <i>JAMA Neurology</i> , 2017, 74, 1206.	4.5	72
260	Direct oral anticoagulant reversal: how, when and issues faced. <i>Expert Review of Hematology</i> , 2017, 10, 1005-1022.	1.0	4
261	Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents. <i>Internal and Emergency Medicine</i> , 2017, 12, 1101-1108.	1.0	14
262	2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. <i>Journal of Arrhythmia</i> , 2017, 33, 345-367.	0.5	141

#	ARTICLE	IF	CITATIONS
263	Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures. Expert Opinion on Biological Therapy, 2017, 17, 1275-1296.	1.4	10
264	Interruption of non-vitamin K antagonist anticoagulants in patients undergoing planned invasive procedures: how long is long enough?. European Heart Journal, 2017, 38, 2440-2443.	1.0	6
265	Incorporating Comprehensive Management of Direct Oral Anticoagulants into Anticoagulation Clinics. Pharmacotherapy, 2017, 37, 1284-1297.	1.2	20
266	Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015. European Journal of Clinical Pharmacology, 2017, 73, 1417-1425.	0.8	69
267	Vitamin K Antagonists Versus Novel Oral Anticoagulants for Elective Electrical Cardioversion of Atrial Fibrillation. American Journal of Therapeutics, 2017, 24, e553-e558.	0.5	2
268	Evaluation of left atrial thrombus prior to catheter ablation of atrial fibrillation: Is it time for an individualized approach?. Journal of Cardiovascular Electrophysiology, 2017, 28, 1137-1139.	0.8	1
269	Bleeding-related hospital admissions and 30-day readmissions in patients with non-valvular atrial fibrillation treated with dabigatran versus warfarin. Journal of Thrombosis and Haemostasis, 2017, 15, 1923-1933.	1.9	15
270	Management of dental patients receiving antiplatelet therapy or chronic oral anticoagulation: A review of the latest evidence. European Journal of General Practice, 2017, 23, 197-202.	0.9	30
271	ANMCO Position Paper: direct oral anticoagulants for stroke prevention in atrial fibrillation: clinical scenarios and future perspectives. European Heart Journal Supplements, 2017, 19, D70-D88.	0.0	6
272	The relationship of renal function to outcome: A post hoc analysis from the Edoxaban versus warfarin in subjects Undergoing cardioversion of Atrial Fibrillation (ENSURE-AF) study. American Heart Journal, 2017, 193, 16-22.	1.2	9
273	Terapia puente en los pacientes anticoagulados: ¿todavía esa es la cuestión?. Medicina Clínica, 2017, 149, 303-304.	0.3	0
274	Oral anticoagulation for stroke prevention amongst atrial fibrillation patients with valvular heart disease. Current Opinion in Cardiology, 2017, 32, 174-180.	0.8	9
275	Evolving cardiovascular uses of direct-acting oral anticoagulants: a paradigm shift on the horizon?. Internal and Emergency Medicine, 2017, 12, 923-934.	1.0	4
276	A retrospective study on the risk factors for bleeding events in warfarin therapy, focusing on renal function. European Journal of Clinical Pharmacology, 2017, 73, 1491-1497.	0.8	5
277	Recent Advances in Stroke Prevention in Patients with Atrial Fibrillation and End-Stage Renal Disease. CardioRenal Medicine, 2017, 7, 207-217.	0.7	13
278	Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K) Tj ETQq1 1 0.784314 rgBT /Overbo Cardiology. 2017. 120. 1837-1840.	0.7	10
279	Once- versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation. Expert Opinion on Pharmacotherapy, 2017, 18, 1325-1332.	0.9	23
280	Association of Atrial Fibrillation and Oral Anticoagulant Use With Perioperative Outcomes After Major Noncardiac Surgery. Journal of the American Heart Association, 2017, 6, .	1.6	8

#	ARTICLE	IF	CITATIONS
281	Reversal Strategies for Newer Oral Anticoagulants. AACN Advanced Critical Care, 2017, 28, 322-331.	0.6	4
282	Safe administration of non-vitamin K antagonist oral anticoagulants. NursePrescribing, 2017, 15, 238-245.	0.1	0
285	Risk stratification of patients with left atrial appendage thrombus prior to catheter ablation of atrial fibrillation: An approach towards an individualized use of transesophageal echocardiography. Journal of Cardiovascular Electrophysiology, 2017, 28, 1127-1136.	0.8	20
286	Once- or twice-daily non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A meta-analysis of randomized controlled trials. Journal of the Formosan Medical Association, 2017, 116, 591-598.	0.8	8
288	Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic Drugs. Drug Safety, 2017, 40, 1091-1098.	1.4	15
289	Idarucizumab for Dabigatran Reversal – Full Cohort Analysis. New England Journal of Medicine, 2017, 377, 431-441.	13.9	858
290	Management of arrhythmias: NOACs, digoxin, alcohol, light, and devices. European Heart Journal, 2017, 38, 2081-2085.	1.0	0
291	Insertion of miniaturized cardiac monitors outside the catheter operating room: experience and practical advice. Europace, 2017, 19, 1624-1629.	0.7	13
293	Findings of transoesophageal echocardiogram in appropriately anticoagulated patients with persistent atrial fibrillation prior to planned cardioversion. BMC Cardiovascular Disorders, 2017, 17, 67.	0.7	14
294	Drug therapy in anticoagulation: which drug for which patient?. Clinical Medicine, 2017, 17, 233-244.	0.8	9
295	Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence. Therapeutic Advances in Drug Safety, 2017, 8, 67-75.	1.0	40
296	Clinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 113-122.	1.5	5
297	Impact of valvular heart disease on oral anticoagulant therapy in non-valvular atrial fibrillation: results from the RAMSES study. Journal of Thrombosis and Thrombolysis, 2017, 43, 157-165.	1.0	3
298	Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: Updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP) – September 2015. Anaesthesia, Critical Care & Pain Medicine, 2017, 36, 73-76.	0.6	66
299	Qu� hacer ante una cirug�a urgente en pacientes tratados con anticoagulantes orales de acci�n directa. Angiologia, 2017, 69, 135-136.	0.0	0
300	Management of radial artery perforation during transradial catheterization using a polytetrafluoroethylene-covered coronary stent. Cardiovascular Revascularization Medicine, 2017, 18, 133-135.	0.3	9
301	Administraci�n simult�nea de rivaroxab�n y dronedarona en pacientes con fibrilaci�n auricular no valvular. Revista Espanola De Cardiologia, 2017, 70, 121-122.	0.6	6
302	Uso de la anticoagulaci�n oral en el paciente sometido a un procedimiento invasivo. Revista Clinica Espanola, 2017, 217, 103-107.	0.2	2

#	ARTICLE	IF	CITATIONS
303	Continuation of direct oral anticoagulants in the acute phase of ischemic stroke. A case series. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 248-251.	1.0	4
304	Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion. <i>Annals of Hematology</i> , 2017, 96, 549-558.	0.8	48
305	Concomitant Rivaroxaban and Dronedaron Administration in Patients With Nonvalvular Atrial Fibrillation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 121-122.	0.4	4
306	Factors Affecting Patients' Perception On, and Adherence To, Anticoagulant Therapy: Anticipating the Role of Direct Oral Anticoagulants. <i>Patient</i> , 2017, 10, 163-185.	1.1	36
307	Influence of periprocedural anticoagulation strategies on complication rate and hospital stay in patients undergoing catheter ablation for persistent atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2017, 106, 38-48.	1.5	8
309	Financial Impact of Direct-Acting Oral Anticoagulants in Medicaid: Budgetary Assessment Based on Number Needed to Treat. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 203-214.	1.0	4
310	Incidence of severe renal dysfunction among individuals taking warfarin and implications for non-vitamin K oral anticoagulants. <i>American Heart Journal</i> , 2017, 184, 150-155.	1.2	18
311	Antiplatelet and Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Coronary Stenting. <i>Interventional Cardiology Clinics</i> , 2017, 6, 91-117.	0.2	4
312	Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Clinical Practice: Focus on Rivaroxaban in Stroke Prevention in Patients With Atrial Fibrillation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 711-724.	0.7	2
313	Acute Management of Anticoagulation-Associated Intracerebral Hemorrhage. <i>Neurology International Open</i> , 2017, 01, E275-E286.	0.4	2
314	A case report of parenchymal hematoma after intravenous thrombolysis in a rivaroxaban-treated patient. <i>Medicine (United States)</i> , 2017, 96, e9435.	0.4	4
315	ANMCO Position Paper: the use of non-vitamin K dependent new oral anticoagulant(s) in pulmonary embolism therapy and prevention. <i>European Heart Journal Supplements</i> , 2017, 19, D293-D308.	0.0	4
316	Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulaci3n Cardíaca y. <i>Europace</i> , 2017, 19, 1757-1758.	0.7	107
317	Evaluation of the Appropriateness of Direct Oral Anticoagulant Selection and Monitoring in the Outpatient Setting. <i>Journal of Pharmacy Technology</i> , 2017, 33, 108-113.	0.5	3
318	Adherence to oral anticoagulant therapy in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2017, 117, 209-218.	1.8	161
319	An update on the bleeding risks associated with DOACs. <i>Drug and Therapeutics Bulletin</i> , 2017, 55, 129-132.	0.3	6
320	Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Es. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2215-2236.	1.8	41
321	Neurosurgery in a patient at peak levels of rivaroxaban: taking into account all factors. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017, 1, 296-300.	1.0	5

#	ARTICLE	IF	CITATIONS
322	Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. <i>BMJ: British Medical Journal</i> , 2017, 356, j510.	2.4	275
323	Pharmacological profile of non-vitamin K antagonist oral anticoagulants. <i>African Journal of Pharmacy and Pharmacology</i> , 2017, 11, 125-136.	0.2	4
324	A pilot process to identify and switch high-risk warfarin patients to direct oral anticoagulants. <i>Journal of Hospital Administration</i> , 2017, 6, 20.	0.0	0
325	PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS. <i>Rational Pharmacotherapy in Cardiology</i> , 2017, 13, 756-763.	0.3	0
326	Update on Direct Oral AntiCoagulants (DOACs). <i>Hamostaseologie</i> , 2017, 37, 267-275.	0.9	9
327	Direct oral anticoagulants (DOAC) – Management of emergency situations. <i>Hamostaseologie</i> , 2017, 37, 257-266.	0.9	19
329	DOAC use in patients with chronic kidney disease. <i>Hamostaseologie</i> , 2017, 37, 286-294.	0.9	5
330	Current Situation of Medication Adherence in Hypertension. <i>Frontiers in Pharmacology</i> , 2017, 8, 100.	1.6	173
331	The timing of the resumption of anticoagulants and its relationship to clinical outcomes in patients with intracerebral hemorrhage. <i>Nosotchu</i> , 2017, 39, 339-343.	0.0	1
332	Reversal of direct oral anticoagulants. <i>Vascular Health and Risk Management</i> , 2017, Volume 13, 287-292.	1.0	27
333	Consensus Document of the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Association of Interventional Cardiology (SICI-GISE) and Italian Society of Cardiac Surgery (SICCH): clinical approach to pharmacologic pre-treatment for patients undergoing myocardial revascularization procedures. <i>European Heart Journal Supplements</i> , 2017, 19, D151-D162.	0.0	1
334	Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. <i>World Journal of Gastroenterology</i> , 2017, 23, 1954.	1.4	146
335	Real-world Data and Recommended Dosage of Non-vitamin K Oral Anticoagulants for Korean Patients. <i>Korean Circulation Journal</i> , 2017, 47, 833.	0.7	12
336	Management of anticoagulation in hip fractures. <i>EFORT Open Reviews</i> , 2017, 2, 394-402.	1.8	31
337	Practical guidance on the use of laboratory testing in the management of bleeding in patients receiving direct oral anticoagulants. <i>Vascular Health and Risk Management</i> , 2017, Volume 13, 457-467.	1.0	40
338	Apixaban - Metabolism, Pharmacologic Properties and Drug Interactions. <i>Current Drug Metabolism</i> , 2017, 18, 609-621.	0.7	23
339	The hemorrhagic transformation index score: a prediction tool in middle cerebral artery ischemic stroke. <i>BMC Neurology</i> , 2017, 17, 177.	0.8	40
340	Timing of Treatment Initiation With Oral Anticoagulants for Acute Ischemic Stroke in Patients With Nonvalvular Atrial Fibrillation. <i>Circulation Journal</i> , 2017, 81, 180-184.	0.7	16

#	ARTICLE	IF	CITATIONS
341	Timing of Anticoagulant Therapy After Acute Ischemic Stroke. <i>Circulation Journal</i> , 2017, 81, 151-152.	0.7	0
342	CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION. <i>Rational Pharmacotherapy in Cardiology</i> , 2017, 13, 45-50.	0.3	2
343	Medicina interna perioperatoria - Il paziente chirurgico complesso: il ruolo dell'internista nell'ospedale snello, a misura del paziente, organizzato per intensità di cure. <i>Italian Journal of Medicine</i> , 2017, 5, 1.	0.2	1
344	Managing direct oral anticoagulants for scheduled or emergency surgery: new proposals from the Perioperative Haemostasis Interest Group. <i>Sang Thrombose Vaisseaux</i> , 2017, 29, 106-116.	0.1	1
345	Non-vitamin-K-dependent Oral Anticoagulants in End-stage Renal Disease Patients with Non-valvular Atrial Fibrillation: An Impossible Wedding?. <i>Giornale De Tecniche Nefrologiche & Dialitiche</i> , 2017, 29, 117-126.	0.1	0
346	Management of oral antiplatelet agents and anticoagulation therapy before bronchoscopy. <i>Journal of Thoracic Disease</i> , 2017, 9, S1022-S1033.	0.6	19
347	Care pathways in thrombosis management: the INNOVATE peer-to-peer educational initiative. <i>Advances in Medical Education and Practice</i> , 2017, Volume 8, 195-203.	0.7	0
348	Stroke prevention in atrial fibrillation. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2017, 47, 13-23.	0.2	3
349	Anticoagulation therapy in the elderly with non-valvular atrial fibrillation: a double-edged sword. <i>Geriatric Care</i> , 2017, 3, .	0.2	4
350	Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa. <i>Blood Advances</i> , 2017, 1, 1827-1838.	2.5	50
351	DRUG INTERACTIONS OF NEW ORAL ANTICOAGULANTS: INSIDE AND OUTSIDE TABLE CELLS. <i>Rational Pharmacotherapy in Cardiology</i> , 2017, 13, 716-724.	0.3	0
352	Catheter Ablation versus Thoracoscopic Surgical Ablation in Long Standing Persistent Atrial Fibrillation (CASA-AF): study protocol for a randomised controlled trial. <i>Trials</i> , 2018, 19, 117.	0.7	7
353	Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Serious Liver Injury. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1105-1113.	1.2	36
354	Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>European Heart Journal</i> , 2018, 39, 2314-2325.	1.0	186
355	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. <i>Hematological Oncology</i> , 2018, 36, 624-632.	0.8	55
356	Suspected adverse drug reaction reports with oral anticoagulants in Portugal: a pharmacovigilance study. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 339-345.	1.0	5
357	Type and doses of oral anticoagulants and adherence to anticoagulant treatment in elderly patients with atrial fibrillation: the ESPARTA study. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 223-232.	0.6	14
358	Management of dental patients taking direct oral anticoagulants: Dabigatran. <i>Oral Diseases</i> , 2018, 24, 228-232.	1.5	7

#	ARTICLE	IF	CITATIONS
359	Drug Interactions With Non-Vitamin K Oral Anticoagulants. JAMA - Journal of the American Medical Association, 2018, 319, 827.	3.8	9
360	Preventability of serious thromboembolic and bleeding events related to the use of oral anticoagulants: a prospective study. British Journal of Clinical Pharmacology, 2018, 84, 1544-1556.	1.1	17
361	Drug Interactions With Non-Vitamin K Oral Anticoagulants. JAMA - Journal of the American Medical Association, 2018, 319, 828.	3.8	8
362	Drug Interactions With Non-Vitamin K Oral Anticoagulants. JAMA - Journal of the American Medical Association, 2018, 319, 829.	3.8	8
363	Drug Interactions With Non-Vitamin K Oral Anticoagulants. JAMA - Journal of the American Medical Association, 2018, 319, 829.	3.8	10
364	Drug Interactions With Non-Vitamin K Oral Anticoagulants. JAMA - Journal of the American Medical Association, 2018, 319, 830.	3.8	5
365	Drug Interactions With Non-Vitamin K Oral Anticoagulants—Reply. JAMA - Journal of the American Medical Association, 2018, 319, 830.	3.8	5
366	Risk factors and prevention of dabigatran-related gastrointestinal bleeding in patients with atrial fibrillation. Journal of Arrhythmia, 2018, 34, 30-35.	0.5	8
367	A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery. JACC: Cardiovascular Interventions, 2018, 11, 417-434.	1.1	81
368	Oral anticoagulant use in cardiovascular disorders: a perspective on present and potential indications for rivaroxaban. Current Medical Research and Opinion, 2018, 34, 1945-1957.	0.9	2
369	Transitioning Between Anticoagulants. , 2018, , 133-150.		0
372	Antithrombotic Therapy for Patients with Atrial Fibrillation. , 2018, , 217-238.		0
374	State of play and future direction with NOACs: An expert consensus. Vascular Pharmacology, 2018, 106, 9-21.	1.0	9
375	What Surgeons Should Know About Non-Vitamin K Oral Anticoagulants. JAMA Surgery, 2018, 153, 577.	2.2	29
376	Quality of direct oral anticoagulant prescribing in elderly patients with non-valvular atrial fibrillation: results from a large urban health system. Journal of Thrombosis and Thrombolysis, 2018, 46, 1-6.	1.0	7
377	Contemporary approach to stroke prevention in atrial fibrillation: Risks, benefits, and new options. Trends in Cardiovascular Medicine, 2018, 28, 469-480.	2.3	1
378	Periprocedural Management of Direct Oral Anticoagulants Surrounding Cardioversion and Invasive Electrophysiological Procedures. Cardiology in Review, 2018, 26, 245-254.	0.6	2
379	Structure and function of anticoagulation clinics in the United States: an AC forum membership survey. Journal of Thrombosis and Thrombolysis, 2018, 46, 7-11.	1.0	21

#	ARTICLE	IF	CITATIONS
380	The role of cardiologists in stroke prevention and treatment: position paper of the European Society of Cardiology Council on Stroke. <i>European Heart Journal</i> , 2018, 39, 1567-1573.	1.0	21
381	A single institution's experience with using dabigatran, rivaroxaban and warfarin for prevention of thromboembolism in atrial fibrillation. <i>Proceedings of Singapore Healthcare</i> , 2018, 27, 20-25.	0.2	4
382	Variation of renal function over time is associated with major bleeding in patients treated with direct oral anticoagulants for atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 833-841.	1.9	31
383	Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting. <i>Oncologist</i> , 2018, 23, 822-839.	1.9	24
384	Direct oral anticoagulants versus warfarin: is new always better than the old?. <i>Open Heart</i> , 2018, 5, e000712.	0.9	61
385	Fatal Adverse Event with Dabigatran in Elderly Patient with Reduced Kidney Function. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 123, 221-226.	1.2	3
386	The EXPAND study: Efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillation. <i>International Journal of Cardiology</i> , 2018, 258, 126-132.	0.8	40
388	Kidney function monitoring and nonvitamin K oral anticoagulant dosage in atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12907.	1.7	13
389	Managing anticoagulation in patients receiving implantable cardiac devices. <i>Future Cardiology</i> , 2018, 14, 151-164.	0.5	1
390	Management of the Trauma Patient on Direct Oral Anticoagulants. <i>Current Anesthesiology Reports</i> , 2018, 8, 107-118.	0.9	0
391	Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 345-352.	1.0	26
392	Contemporary utilization of antithrombotic therapy for stroke prevention in patients with atrial fibrillation: an audit in an Australian hospital setting. <i>Therapeutic Advances in Drug Safety</i> , 2018, 9, 97-111.	1.0	10
393	Residual rivaroxaban exposure after discontinuation of anticoagulant therapy in patients undergoing cardiac catheterization. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 611-618.	0.8	5
394	Incidence of intracardiac thrombus formation prior to electrical cardioversion in respect to the mode of oral anticoagulation. <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 537-547.	0.8	14
395	Reversal agents for non-vitamin K antagonist oral anticoagulants. <i>Nature Reviews Cardiology</i> , 2018, 15, 273-281.	6.1	116
396	Antiarrhythmic drugs' clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). Europace , 2018, 20, 731-732am.	0.7	144
397	Point of Care Testing (POCT) to assess drug concentration in patients treated with non-vitamin K antagonist oral anticoagulants (NOACs). <i>Thrombosis Research</i> , 2018, 163, 100-104.	0.8	11
398	Spontaneous Cervical Spinal Epidural Hematoma Associated with Dabigatran. <i>World Neurosurgery</i> , 2018, 112, 264-266.	0.7	10

#	ARTICLE	IF	CITATIONS
399	Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants. <i>European Journal of Neurology</i> , 2018, 25, 747.	1.7	60
400	Efficacy and Safety Outcomes of Direct Oral Anticoagulants and Amiodarone in Patients with Atrial Fibrillation. <i>American Journal of Medicine</i> , 2018, 131, 573.e1-573.e8.	0.6	19
401	Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants. <i>British Journal of Anaesthesia</i> , 2018, 120, 645-656.	1.5	115
402	Bleeding Complications After Use of Novel Oral Anticoagulants in Patients Undergoing Cardiac Surgery. <i>Annals of Thoracic Surgery</i> , 2018, 105, 702-708.	0.7	32
403	Discrepancies between the use of MDRD-4 IDMS and CKD-EPI equations, instead of the Cockcroft-Gault equation, in the determination of the dosage of direct oral anticoagulants in patients with non-valvular atrial fibrillation. <i>Medicina Clínica (English Edition)</i> , 2018, 150, 85-91.	0.1	6
404	Anticoagulantes orales directos: puesta al día. <i>Medicina Clínica</i> , 2018, 151, 198-206.	0.3	23
405	Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial. <i>American Heart Journal</i> , 2018, 196, 105-112.	1.2	80
406	Direct Oral Anticoagulants in End-Stage Renal Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 353-363.	1.5	16
407	Underuse of Vitamin K Antagonist and Direct Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A Contemporary Review. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 301-310.	2.3	25
408	Comparison of Anticoagulant Therapy for Atrial Fibrillation - Novel Oral Anticoagulants Versus Vitamin K Antagonists. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 514-523.	1.6	11
409	Innovative strategies to improve adherence to non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation. <i>European Heart Journal</i> , 2018, 39, 1404-1406.	1.0	10
410	Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time—A RE-LY trial analysis. <i>American Heart Journal</i> , 2018, 198, 169-177.	1.2	14
411	Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage. <i>Annals of Neurology</i> , 2018, 83, 186-196.	2.8	114
412	The CHA2DS2-VASc score strongly correlates with glomerular filtration rate and predicts renal function decline over time in elderly patients with atrial fibrillation and chronic kidney disease. <i>International Journal of Cardiology</i> , 2018, 253, 71-77.	0.8	24
413	Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIA Registry. <i>Europace</i> , 2018, 20, 1577-1583.	0.7	93
414	Nonvitamin K Antagonist Oral Anticoagulants Use in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves/Prior Surgical Valve Repair: A Multicenter Clinical Practice Experience. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 364-369.	1.5	38
415	Telemonitoring-based feedback improves adherence to non-vitamin K antagonist oral anticoagulants intake in patients with atrial fibrillation. <i>European Heart Journal</i> , 2018, 39, 1394-1403.	1.0	52
416	Drug plasma level measurement in management of severe bleeding during direct oral anticoagulant treatment: case report and perspective. <i>Internal and Emergency Medicine</i> , 2018, 13, 1093-1096.	1.0	5

#	ARTICLE	IF	CITATIONS
417	Management of bleeding and emergency invasive procedures in patients on dabigatran: Updated guidelines from the French Working Group on Perioperative Haemostasis (GIHP) – September 2016. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2018, 37, 391-399.	0.6	36
418	Non-Vitamin K-Dependent Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With CKD: Pragmatic Considerations for the Clinician. <i>American Journal of Kidney Diseases</i> , 2018, 72, 717-727.	2.1	19
419	Reversal of direct oral anticoagulants. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2018, 79, C70-C73.	0.2	0
420	Non-bleeding Adverse Events with the Use of Direct Oral Anticoagulants: A Sequence Symmetry Analysis. <i>Drug Safety</i> , 2018, 41, 881-897.	1.4	28
421	Anticancer Drug-Related Nonvalvular Atrial Fibrillation: Challenges in Management and Antithrombotic Strategies. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 388-396.	1.5	19
422	Atrial fibrillation patient preferences for oral anticoagulation and stroke knowledge: Results of a conjoint analysis. <i>Clinical Cardiology</i> , 2018, 41, 855-861.	0.7	31
423	Design and baseline characteristics of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS). <i>Journal of Arrhythmia</i> , 2018, 34, 167-175.	0.5	13
424	Recomendaciones del Grupo Catal�n de Trombosis (Tromboc@t Working Group) para el tratamiento de los pacientes que reciben anticoagulantes orales directos. <i>Medicina Cl�nica</i> , 2018, 151, 210.e1-210.e13.	0.3	2
425	Peri-Procedural Management of Oral Anticoagulants in the DOAC Era. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 600-606.	1.6	25
426	Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. <i>Nature Reviews Nephrology</i> , 2018, 14, 337-351.	4.1	89
427	Oral anticoagulants for atrial fibrillation and acute coronary syndrome with or without stenting. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, e40-e45.	0.6	2
428	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. <i>Europace</i> , 2018, 20, 1231-1242.	0.7	194
429	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>European Heart Journal</i> , 2018, 39, 1330-1393.	1.0	1,576
430	Oral anticoagulant therapy in adults with congenital heart disease and atrial arrhythmias: Implementation of guidelines. <i>International Journal of Cardiology</i> , 2018, 257, 67-74.	0.8	8
431	Stroke, thromboembolism and bleeding in patients with atrial fibrillation according to the EHRA valvular heart disease classification. <i>International Journal of Cardiology</i> , 2018, 260, 93-98.	0.8	15
432	Major knowledge gaps and system barriers to guideline implementation among European physicians treating patients with atrial fibrillation: a European Society of Cardiology international educational needs assessment. <i>Europace</i> , 2018, 20, 1919-1928.	0.7	37
433	Gastrointestinal endoscopy in patients receiving novel direct oral anticoagulants: results from the prospective Dresden NOAC registry. <i>Journal of Gastroenterology</i> , 2018, 53, 236-246.	2.3	19
434	Direct Oral Anticoagulants for Thromboprophylaxis in Patients with Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 427-438.	1.5	13

#	ARTICLE	IF	CITATIONS
435	Periprocedural management of patients receiving novel oral anticoagulants. <i>European Journal of Hospital Pharmacy</i> , 2018, 25, 292-297.	0.5	2
436	Potential Causes and Implications of Low Target Therapeutic Ratio in Warfarin-Treated Patients for Thrombosis Prophylaxis: A Single-Center Experience. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 536-541.	0.7	1
437	Practical perspectives on the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation: A view from the Middle East and North Africa. <i>Journal of the Saudi Heart Association</i> , 2018, 30, 122-139.	0.2	9
438	Management of Direct-Acting Oral Anticoagulants Surrounding Dental Procedures With Low-to-Moderate Risk of Bleeding. <i>Journal of Pharmacy Practice</i> , 2018, 31, 202-207.	0.5	15
439	2017 EACTS Guidelines on perioperative medication in adult cardiac surgery. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 5-33.	0.6	292
440	2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). <i>European Heart Journal</i> , 2018, 39, 763-816.	1.0	2,305
441	Atrial fibrillation in kidney transplant recipients: is there a place for the novel drugs?. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1304-1309.	0.4	24
442	Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and End-Stage Renal Disease. <i>American Journal of Cardiology</i> , 2018, 121, 131-140.	0.7	15
443	Elective Cardioversion in the Era of Novel Oral Anticoagulants – Does a Nurse Administered Verbal Questionnaire for Compliance Negate the Need for Routine Transoesophageal Echocardiography?. <i>Heart Lung and Circulation</i> , 2018, 27, 989-994.	0.2	2
444	Renal function and risk of stroke and bleeding in patients undergoing catheter ablation for atrial fibrillation: Comparison between uninterrupted direct oral anticoagulants and warfarin administration. <i>Heart Rhythm</i> , 2018, 15, 348-354.	0.3	10
445	Guideline for stopping anticoagulants prior to urological procedures. <i>Journal of Clinical Urology</i> , 2018, 11, 271-279.	0.1	3
446	Use of Guidelines for Reducing Stroke Risk in Patients With Nonvalvular Atrial Fibrillation: A Review From a Latin American Perspective. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 22-32.	0.7	11
447	Evaluation of the predictive performance of bleeding risk scores in patients with nonvalvular atrial fibrillation on oral anticoagulants. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018, 43, 209-219.	0.7	8
448	Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: Why we should not underdose our patients. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 85-94.	0.7	29
449	Symptoms, acceptance of illness and health-related quality of life in patients with atrial fibrillation. <i>European Journal of Cardiovascular Nursing</i> , 2018, 17, 262-272.	0.4	23
450	Prevention of Stroke in Atrial Fibrillation. , 2018, , 1092-1100.		0
451	Editor's Choice – 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). <i>European Journal of Vascular and Endovascular Surgery</i> , 2018, 55, 305-368.	0.8	734
452	Decision Algorithms for Direct Oral Anticoagulant Use in Patients With Nonvalvular Atrial Fibrillation: A Practical Guide for Neurologists. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 396-404.	0.7	2

#	ARTICLE	IF	CITATIONS
453	Update on the use of direct oral anticoagulants for the prevention and treatment of thromboembolism. <i>Future Cardiology</i> , 2018, 14, 89-99.	0.5	0
454	Dabigatran level monitoring prior to idarucizumab administration in patients requiring emergent cardiac surgery. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 9-12.	1.0	11
455	Overview of Anticoagulation Agents. , 2018, , 275-289.		0
456	Medical Management of Pulmonary Embolism. , 2018, , 371-387.		0
457	Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 209-219.	1.9	266
458	Use of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Malignancy: Clinical Practice Experience in a Single Institution and Literature Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 370-376.	1.5	39
459	Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 54-64.	1.9	41
460	European guidelines on perioperative venous thromboembolism prophylaxis. <i>European Journal of Anaesthesiology</i> , 2018, 35, 96-107.	0.7	15
461	Ritonavir-Boosted Protease Inhibitors but Not Cobicistat Appear Safe in HIV-Positive Patients Ingesting Dabigatran. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	6
462	Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, e27-e33.	0.7	16
463	Discrepancias entre el empleo de las ecuaciones MDRD-4 IDMS y CKD-EPI en vez de la de Cockcroft-Gault en la determinación de la posología de los anticoagulantes orales directos en pacientes con fibrilación auricular no valvular. <i>Medicina Clínica</i> , 2018, 150, 85-91.	0.3	10
464	Patients with atrial fibrillation and coronary artery disease – Double trouble. <i>Advances in Medical Sciences</i> , 2018, 63, 30-35.	0.9	142
466	THROMBOSIS OF LEFT ATRIAL APPENDAGE DURING THERAPY WITH DIRECT ORAL ANTICOAGULANT. CLINICAL CASE. <i>Rational Pharmacotherapy in Cardiology</i> , 2018, 14, 350-355.	0.3	1
467	Risk Factors of Gastrointestinal Bleeding in Patients Receiving New Oral Anticoagulants. <i>The Korean Journal of Helicobacter and Upper Gastrointestinal Research</i> , 2018, 18, 219.	0.1	2
469	Direct oral anticoagulants in non-valvular atrial fibrillation in elderly: for a treatment adapted to patient profile. <i>Psychologie & Neuropsychiatrie Du Vieillissement</i> , 2018, 16, 229-240.	0.2	3
470	Diagnosis and Treatment of Pulmonary Embolism in Challenging Populations. <i>Hamostaseologie</i> , 2018, 38, 87-97.	0.9	2
471	Initial and Long-Term Treatment of Pulmonary Embolism: Current Approach and Future Perspectives. <i>Hamostaseologie</i> , 2018, 38, 75-86.	0.9	2
472	Appropriateness of DOAC Prescribing Before and During Hospital Admission and Analysis of Determinants for Inappropriate Prescribing. <i>Frontiers in Pharmacology</i> , 2018, 9, 1220.	1.6	50

#	ARTICLE	IF	CITATIONS
473	Pulmonary Embolism: Contemporary Medical Management and Future Perspectives. <i>Annals of Vascular Diseases</i> , 2018, 11, 265-276.	0.2	3
474	2018 Korean Guideline of Atrial Fibrillation Management. <i>Korean Circulation Journal</i> , 2018, 48, 1033.	0.7	108
475	Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions. <i>Blood</i> , 2018, 132, 2230-2239.	0.6	54
476	Newer Oral Anticoagulants. , 2018, , 137-145.		0
477	Limitations of Specific Coagulation Tests for Direct Oral Anticoagulants: A Critical Analysis. <i>Journal of the American Heart Association</i> , 2018, 7, e009807.	1.6	40
480	New oral anti-coagulation drugs and prostate biopsy: a call for guidelines. <i>Therapeutic Advances in Urology</i> , 2018, 10, 437-443.	0.9	4
481	New score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs. <i>Open Heart</i> , 2018, 5, e000931.	0.9	22
482	The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review. <i>International Journal of Emergency Medicine</i> , 2018, 11, 55.	0.6	25
484	Uso de anticoagulantes orales en situaciones clínicas complejas con fibrilación auricular. <i>Medicina Clínica</i> , 2018, 150, 8-24.	0.3	2
485	International consensus statement on the perioperative management of direct oral anticoagulants in cardiac surgery. <i>Anaesthesia</i> , 2018, 73, 1535-1545.	1.8	49
486	Tromboc@t Working Group recommendations for management in patients receiving direct oral anticoagulants. <i>Medicina Clínica (English Edition)</i> , 2018, 151, 210.e1-210.e13.	0.1	0
487	RE-CIRCUIT: uninterrupted anticoagulation with dabigatran to cover left atrial ablation procedures. <i>Cardiovascular Research</i> , 2018, 114, e89-e90.	1.8	0
488	Pharmacokinetics of new oral anticoagulants: implications for use in routine care. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 1057-1069.	1.5	37
489	Bleeding in patients receiving non-vitamin K oral anticoagulants: clinical trial evidence. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2018, 12, 361-380.	1.0	17
490	Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: Potential for drug-drug interactions. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 132, 169-179.	2.0	39
492	Risk Controlling of Gastrointestinal Bleeding in Comorbid Patients with Cardiovascular Diseases. <i>Rational Pharmacotherapy in Cardiology</i> , 2018, 14, 583-590.	0.3	4
493	Impact of Renal Function on Outcomes With Edoxaban in Real-World Patients With Atrial Fibrillation. <i>Stroke</i> , 2018, 49, 2421-2429.	1.0	42
495	APPROACHES TO THE CHOICE OF ANTICOAGULANT THERAPY IN THE TREATMENT OF PATIENTS WITH COMBINATION OF ATRIAL FIBRILLATION WITH CORONARY HEART DISEASE OR PERIPHERAL ATHEROSCLEROSIS: POTENTIAL OF APIXABAN. <i>Rational Pharmacotherapy in Cardiology</i> , 2018, 14, 441-450.	0.3	0

#	ARTICLE	IF	CITATIONS
496	Anticoagulants in frail patients. Seven situations at risk. JMV-Journal De Medecine Vasculaire, 2018, 43, 302-309.	0.1	1
497	Functional Outcome and Safety of Intracranial Thrombectomy After Emergent Extracranial Stenting in Acute Ischemic Stroke Due to Tandem Occlusions. Frontiers in Neurology, 2018, 9, 940.	1.1	14
498	The Significance of Drug-Drug and Drug-Food Interactions of Oral Anticoagulation. Arrhythmia and Electrophysiology Review, 2018, 7, 55.	1.3	96
499	Direct current cardioversion. Medicine, 2018, 46, 663.	0.2	1
500	Interruption and Reversal of Direct Oral Anticoagulants in Preprocedural and Acute Settings. Journal of the American Board of Family Medicine, 2018, 31, 817-827.	0.8	2
501	Patient characteristics and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban or vitamin K antagonists: real-world evidence from Italian administrative databases. Journal of Comparative Effectiveness Research, 2018, 7, 1063-1071.	0.6	5
502	Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions. Hematology American Society of Hematology Education Program, 2018, 2018, 339-347.	0.9	35
504	Direct factor Xa inhibitor in the prevention of thromboembolism. Health Problems of Civilization, 2018, 12, 247-254.	0.1	1
505	Impact of creatinine clearance on outcomes in patients with non-valvular atrial fibrillation: a subanalysis of the J-RHYTHM Registry. European Heart Journal Quality of Care & Clinical Outcomes, 2018, 4, 59-68.	1.8	36
506	Continuation or Discontinuation of Anticoagulation in the Early Phase After Acute Ischemic Stroke. Stroke, 2018, 49, 1762-1765.	1.0	11
507	Major bleeding with old and novel oral anticoagulants: How to manage it. Focus on reversal agents. International Journal of Cardiology, 2018, 268, 75-79.	0.8	11
508	Atrial fibrillation in dialysis patients: is there a place for non-vitamin K antagonist oral anticoagulants?. International Urology and Nephrology, 2018, 50, 1633-1642.	0.6	3
509	Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry. Internal and Emergency Medicine, 2018, 13, 1051-1058.	1.0	25
510	Catheter ablation for atrial fibrillation on uninterrupted direct oral anticoagulants: A safe approach. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 1001-1009.	0.5	6
511	Out-of-range INR results lead to increased health-care utilization in four large anticoagulation clinics. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 490-496.	1.0	1
512	Effects and Risks of Heparin Bridging and Different Modes of Interruption/Resumption of Rivaroxaban on Perioperative Complications of Catheter Ablation for Atrial Fibrillation—Another Analysis of the JACRE-R Registry. Circulation Journal, 2018, 82, 346-352.	0.7	5
513	Reducing risk of spinal haematoma from spinal and epidural pain procedures. Scandinavian Journal of Pain, 2018, 18, 129-150.	0.5	14
514	Major bleeding with old and novel oral anticoagulants: How to manage it. Focus on general measures. International Journal of Cardiology, 2018, 268, 80-84.	0.8	5

#	ARTICLE	IF	CITATIONS
515	Safety and efficacy of nonvitamin K antagonist oral anticoagulants during catheter ablation of atrial fibrillation: A systematic review and meta-analysis. <i>Cardiovascular Therapeutics</i> , 2018, 36, e12457.	1.1	8
516	Nonvitamin K Oral Anticoagulants in Patients With Atrial Fibrillation and Severe Renal Dysfunction. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 847-855.	0.4	4
517	Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States. <i>Circulation</i> , 2018, 138, 1519-1529.	1.6	359
518	Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral surgery or dental extractions. <i>The Cochrane Library</i> , 2018, 7, CD012293.	1.5	19
519	Drug Adherence in Hypertension and Cardiovascular Protection. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2018, , .	0.1	5
520	Direct oral anticoagulants: An update. <i>Medicina Clínica (English Edition)</i> , 2018, 151, 198-206.	0.1	15
521	The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 1147-1156.	2.0	75
522	Development and validation of a questionnaire to self-assess patient knowledge of direct oral anticoagulants (KODOA-test). <i>Drug, Healthcare and Patient Safety</i> , 2018, Volume 10, 69-77.	1.0	3
523	Specific Treatment of Acute Intracerebral Hemorrhage. , 2018, , 328-338.		0
524	Medical Therapies. , 2018, , 357-372.		0
525	Management of Anticoagulants in Procedures That Can Cause Bleeding. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 878.	0.4	0
527	Does time from diagnostic CT until surgical evacuation affect outcome in patients with chronic subdural hematoma?. <i>Acta Neurochirurgica</i> , 2018, 160, 1703-1709.	0.9	6
528	Edoxaban Management in Diagnostic and Therapeutic Procedures (EMITâ€AF/VTE)â€™ Trial design. <i>Clinical Cardiology</i> , 2018, 41, 1123-1129.	0.7	9
529	Associations between illness beliefs, medication beliefs, anticoagulationâ€™related quality of life, and INR control: Insights from the Switching Study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 497-507.	1.0	17
530	Discontinuation risk comparison among â€™real-worldâ€™™ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban. <i>PLoS ONE</i> , 2018, 13, e0195950.	1.1	48
531	Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: Practical Considerations on the Choice of Agent and Dosing. <i>Cardiology</i> , 2018, 140, 126-132.	0.6	19
532	Perioperative Management of New Oral Anticoagulants in Urological Surgery. <i>Current Urology</i> , 2018, 11, 169-174.	0.4	8
533	Real clinical experiences of dual versus triple antithrombotic therapy after percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 1239-1246.	0.7	5

#	ARTICLE	IF	CITATIONS
534	Use of Fixed-Dose Combinations in Hypertension and Cardiovascular Disease Prevention. Updates in Hypertension and Cardiovascular Protection, 2018, , 225-235.	0.1	0
535	Variations in clinical management of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation according to different equations for estimating renal function. Internal and Emergency Medicine, 2018, 13, 1059-1067.	1.0	17
536	AApractical guide on how to handle patients with bleeding events while on oral antithrombotic treatment. Netherlands Heart Journal, 2018, 26, 341-351.	0.3	23
537	Variability in Non-Vitamin K Antagonist Oral Anticoagulants Dose Adjustment in Atrial Fibrillation Patients With Renal Dysfunction: The Influence of Renal Function Estimation Formulae. Canadian Journal of Cardiology, 2018, 34, 1010-1018.	0.8	33
538	Direct oral anticoagulants: When to consider laboratory testing?. International Journal of Laboratory Hematology, 2018, 40, 30-33.	0.7	12
539	Direct Oral Anticoagulant Agents: Pharmacologic Profile, Indications, Coagulation Monitoring, and Reversal Agents. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 2049-2058.	0.7	50
540	Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding. Wiener Klinische Wochenschrift, 2018, 130, 722-734.	1.0	4
541	Perioperative antithrombotic therapy in patients undergoing endoscopic urologic surgery: where do we stand with current literature?. Minerva Urology and Nephrology, 2018, 70, 126-136.	1.3	7
542	Antithrombotic Therapy for Atrial Fibrillation. Chest, 2018, 154, 1121-1201.	0.4	718
543	The safety and efficacy of non-vitamin K antagonist oral anticoagulants in atrial fibrillation in the elderly. International Journal of Cardiology, 2018, 265, 118-124.	0.8	18
544	Introduction of direct oral anticoagulant within 7 days of stroke onset: a nomogram to predict the probability of 3-month modified Rankin Scale score ≥ 2 . Journal of Thrombosis and Thrombolysis, 2018, 46, 292-298.	1.0	10
545	Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model. PLoS ONE, 2018, 13, e0195122.	1.1	26
546	Probable pulmonary embolism with repeat administration of prothrombin complex concentrate in a factor Xa inhibitor patient. Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 903-905.	0.7	4
547	Manejo de anticoagulantes en procedimientos que pueden producir una hemorragia. Revista Espanola De Cardiologia, 2018, 71, 878.	0.6	0
548	Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group. Irish Journal of Medical Science, 2019, 188, 101-108.	0.8	23
549	European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS). Europace, 2019, 21, 7-8.	0.7	72
550	Would the Use of Edoxaban Be Cost-effective for the Prevention of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation in Spain?. Revista Espanola De Cardiologia (English Ed), 2019, 72, 398-406.	0.4	6
554	Thrombolysis in an acute ischemic stroke patient with rivaroxaban anticoagulation. Medicine (United Tj ETQq1 1 0,784314 rgBT /Overl	0,4	

#	ARTICLE	IF	CITATIONS
555	2019 Methodology for Heart House Roundtables. Journal of the American College of Cardiology, 2019, 74, 1116-1137.	1.2	4
556	Tranexamic acid to reduce bleeding after dental extraction in patients treated with non-vitamin K oral anticoagulants: design and rationale of the EXTRACT-NOAC trial. British Journal of Oral and Maxillofacial Surgery, 2019, 57, 1107-1112.	0.4	7
557	<p>Clinical Characteristics And Health Care Resources In Patients Treated With Oral Anticoagulants: Evidences From Italian Administrative Databases</p>. Vascular Health and Risk Management, 2019, Volume 15, 429-437.	1.0	1
558	Atrial fibrillation with percutaneous coronary intervention: Navigating the minefield of antithrombotic therapies. Atherosclerosis, 2019, 289, 118-125.	0.4	6
561	Patterns in anticoagulant utilization in the Czech Republic during 2007â€“2017. Journal of Thrombosis and Thrombolysis, 2019, 47, 305-311.	1.0	7
562	Volume replacement strategies do not impair the binding of dabigatran to idarucizumab: Porcine model of hemodilution. PLoS ONE, 2019, 14, e0209350.	1.1	0
563	Oral Manifestations of Systemic Diseases and Their Treatments. , 2019, , 1523-1639.		1
564	Safety of direct oral anticoagulants in realâ€“world clinical practice: translating the trials to everyday clinical management. Expert Opinion on Drug Safety, 2019, 18, 187-209.	1.0	16
565	Pharmacogenetics of anticoagulants used for stroke prevention in patients with atrial fibrillation. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 449-458.	1.5	7
568	Application-based management of perioperative anticoagulant therapy: description of POPACTApp. Langenbeck's Archives of Surgery, 2019, 404, 633-645.	0.8	3
570	Preoperative Management of Oral Anticoagulants. , 2019, , 61-67.		0
571	Anticoagulation Resumption After Stroke from Atrial Fibrillation. Current Atherosclerosis Reports, 2019, 21, 29.	2.0	21
572	Thromboembolic events in patients with atrial fibrillation under anticoagulation. Revista Portuguesa De Cardiologia (English Edition), 2019, 38, 125-127.	0.2	0
573	Creatinine monitoring patterns in the setting of direct oral anticoagulant therapy for non-valvular atrial fibrillation. Journal of Thrombosis and Thrombolysis, 2019, 48, 500-505.	1.0	5
574	Incidence, risk factors, and outcomes of warfarinâ€“associated major bleeding in Thai population. Pharmacoepidemiology and Drug Safety, 2019, 28, 942-950.	0.9	6
575	Anticoagulation in chronic kidney disease: from guidelines to clinical practice. Clinical Cardiology, 2019, 42, 774-782.	0.7	85
576	Creating an Interprofessional guideline to support patients receiving oral anticoagulation therapy: a Delphi exercise. International Journal of Clinical Pharmacy, 2019, 41, 1012-1020.	1.0	7
577	Patient-level adherence and interventions in an interdisciplinary DOAC clinic. Thrombosis Research, 2019, 179, 34-36.	0.8	4

#	ARTICLE	IF	CITATIONS
578	Ischemic stroke in patients previously anticoagulated for non-valvular atrial fibrillation: Why does it happen?. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2019, 38, 117-124.	0.2	4
579	Characteristics in Non-Vitamin K Antagonist Oral Anticoagulant-Related Intracerebral Hemorrhage. <i>Stroke</i> , 2019, 50, 1392-1402.	1.0	21
580	Heparin dosing in uninterrupted anticoagulation with dabigatran vs. warfarin in atrial fibrillation ablation: RE-CIRCUIT study. <i>Europace</i> , 2019, 21, 879-885.	0.7	6
581	Dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A Danish nationwide cohort study. <i>Thrombosis Research</i> , 2019, 178, 101-109.	0.8	11
582	Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016. <i>BMJ Open</i> , 2019, 9, e026645.	0.8	48
583	Comparison of the New Oral Anticoagulants and Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Systematic Review and Meta-Analysis. <i>Drugs in R and D</i> , 2019, 19, 117-126.	1.1	19
585	Rivaroxaban in atrial fibrillation cardioversion: an update. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 613-626.	0.9	5
586	Safety of Apixaban Administered via Nasogastric Tube. <i>Cardiology</i> , 2019, 142, 39-39.	0.6	2
587	Acidente vascular cerebral isqu�mico em doentes previamente anticoagulados por fibrilha� auricular n� valvular: por que acontece?. <i>Revista Portuguesa De Cardiologia</i> , 2019, 38, 117-124.	0.2	12
588	Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1155-1163.	1.6	12
589	Exposure to vitamin k antagonists and kidney function decline in patients with atrial fibrillation and chronic kidney disease. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 207-216.	1.0	20
590	Atrial fibrillation and cancer - An unexplored field in cardiovascular oncology. <i>Blood Reviews</i> , 2019, 35, 59-67.	2.8	64
591	Reversal of dabigatran requiring hemodialysis, fresh frozen plasma, and 2 doses of idarucizumab in a patient with acute kidney injury. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 9-12.	0.5	7
592	Acidentes tromboemb�licos em doentes com fibrilha� auricular sob anticoagula�o. <i>Revista Portuguesa De Cardiologia</i> , 2019, 38, 125-127.	0.2	0
593	Development of New Antithrombotic Regimens for Patients with Acute Coronary Syndrome. <i>Clinical Drug Investigation</i> , 2019, 39, 495-502.	1.1	3
594	Andexanet alfa for the reversal of factor Xa inhibitors. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 387-397.	1.4	10
595	Excessive Prolongation of Coagulation Time During Treatment With Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2019, 35, 736-743.	0.8	3
596	How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism. <i>Blood</i> , 2019, 133, 2269-2278.	0.6	15

#	ARTICLE	IF	CITATIONS
597	Rivaroxaban e malattia renale cronica: evidenze dal presente e prospettive future. <i>Giornale De Tecniche Nefrologiche & Dialitiche</i> , 2019, 31, 30-36.	0.1	0
598	Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: Update and Peri-procedural Management. <i>Critical Care Nurse</i> , 2019, 39, 54-67.	0.5	6
599	Inappropriate non-vitamin K antagonist oral anticoagulants prescriptions: be cautious with dose reductions. <i>Netherlands Heart Journal</i> , 2019, 27, 371-377.	0.3	18
600	Utilization of Anticoagulants in Nonvalvular Atrial Fibrillation Before and After Catheter Ablation at Shanghai, China. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961982626.	0.7	0
601	Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis. <i>Journal of Cardiology</i> , 2019, 73, 515-521.	0.8	15
602	Acute Stroke. <i>Seminars in Neurology</i> , 2019, 39, 061-072.	0.5	26
604	Lifetech LAMbre: a new promising and novel device in the interventional stroke prevention. <i>Future Cardiology</i> , 2019, 15, 405-410.	0.5	4
605	What is the best anticoagulation strategy for patients with atrial fibrillation who experience a stroke while taking a novel oral anticoagulant?. <i>Evidence-Based Practice</i> , 2019, 22, 1-2.	0.0	0
606	Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves. <i>Clinical Therapeutics</i> , 2019, 41, 2549-2557.	1.1	40
607	Andexanet Alfa: Considerations and Practical Applications. <i>Critical Pathways in Cardiology</i> , 2019, 18, 200-206.	0.2	1
608	Severe Enoral Bleeding with a Direct Oral Anticoagulant after Tooth Extraction and Heparin Bridging Treatment. <i>Case Reports in Emergency Medicine</i> , 2019, 2019, 1-5.	0.1	5
609	Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation. <i>Therapeutic Advances in Drug Safety</i> , 2019, 10, 204209861988813.	1.0	28
610	Uninterrupted non-vitamin K antagonist oral anticoagulants during implantation of cardiac implantable electronic devices in patients with atrial fibrillation. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 256-259.	0.6	7
611	Drug causes of intracerebral haemorrhage. <i>Adverse Drug Reaction Bulletin</i> , 2019, 318, 1231-1234.	0.6	1
612	Atrial fibrillation and human immunodeficiency virus type-1 infection: a systematic review. Implications for anticoagulant and antiarrhythmic therapy. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 508-515.	1.1	19
613	Left atrial appendage occlusion using LAMbre Amulet and Watchman in atrial fibrillation. <i>Journal of Cardiology</i> , 2019, 73, 299-306.	0.8	32
614	The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section "Special Situations". <i>Thrombosis and Haemostasis</i> , 2019, 119, 014-038.	1.8	28
615	Risk Factors for Hemorrhagic and Cardioembolic Complications of Intracerebral Hemorrhage Associated with Anticoagulants. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019, 28, 325-329.	0.7	2

#	ARTICLE	IF	CITATIONS
616	Drug-Induced Liver Injury: Highlights of the Recent Literature. <i>Drug Safety</i> , 2019, 42, 365-387.	1.4	82
617	Reduced Doses of Direct Oral Anticoagulants in Ischemic Stroke Patients with Nonvalvular Atrial Fibrillation. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019, 28, 354-359.	0.7	3
618	Idarucizumab administration in a patient with incarcerated bowel hernia. <i>Cor Et Vasa</i> , 2019, 61, 623-624.	0.1	0
619	Patients Taking Oral Anticoagulants for Atrial Fibrillation With Concomitant Complex Disease States. , 2019, , 149-159.		0
620	Neuroanesthesia and Coexisting Renal Problems. , 2019, , 107-154.		0
621	Stroke and Atrial Fibrillation. , 2019, , 161-170.		0
622	Periprocedural Management of Anticoagulation in Patients With Atrial Fibrillation. , 2019, , 105-119.		0
623	Pharmaceutical Care for Patients Receiving Anticoagulation. , 2019, , 369-379.		0
624	Periprocedural Considerations for Anticoagulated Atrial Fibrillation Patients. <i>Journal of Perianesthesia Nursing</i> , 2019, 34, 227-239.	0.3	1
625	Direct Oral Anticoagulants and Medical Comorbidities in Patients Needing Dental Extractions: Management of the Risk of Bleeding. <i>Journal of Oral and Maxillofacial Surgery</i> , 2019, 77, 463-470.	0.5	16
626	Anticoagulation in the Perioperative Period. , 2019, , 721-733.		0
627	Oral Anticoagulation in the Elderly: New Oral Anticoagulantsâ€“Innovative Solution for an Old Problem?. <i>American Journal of Therapeutics</i> , 2019, 26, e133-e142.	0.5	5
628	Preoperative evaluation of adult patients before elective, noncardiothoracic surgery. <i>Der Anaesthetist</i> , 2019, 68, 25-39.	0.5	20
629	Impact of known or new-onset atrial fibrillation on 2-year cardiovascular event rate in patients with acute coronary syndromes: results from the prospective EPICOR Registry. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 121-129.	0.4	31
630	Recomendaciones de la Sociedad EspaÃ±ola de ReumatologÃa sobre sÃndrome antifosfolÃpido primario. Parte II: sÃndrome antifosfolÃpido obstÃ©trico y situaciones especiales. <i>ReumatologÃa ClÃnica</i> , 2020, 16, 133-148.	0.2	4
631	Editorial commentary: Reversal agents in the era of non-vitamin k antagonists oral anticoagulants: Necessity or psychological crutch?. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 91-92.	2.3	1
632	Global thromboelastometry in patients receiving direct oral anticoagulants: the RO-DOA study. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 251-258.	1.0	16
633	Do anticoagulants affect outcomes of hip fracture surgery? A cross-sectional analysis. <i>Archives of Orthopaedic and Trauma Surgery</i> , 2020, 140, 171-176.	1.3	24

#	ARTICLE	IF	CITATIONS
634	Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk. <i>Wiener Klinische Wochenschrift</i> , 2020, 132, 97-109.	1.0	9
635	HAS-BLED score as a predictor of bleeding complications from catheter ablation of atrial fibrillation: A subanalysis of the Japanese Anti-Coagulation Regimen Exploration in AF Catheter Ablation Registries. <i>Journal of Cardiology</i> , 2020, 75, 82-89.	0.8	8
636	Effects of apixaban compared with warfarin as gain in event-free time – a novel assessment of the results of the ARISTOTLE trial. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1311-1319.	0.8	4
637	Beating non-communicable diseases in primary health care: The contribution of pharmacists and guidance from FIP to support WHO goals. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 974-977.	1.5	12
638	Timing of Initiation of Oral Anticoagulation after Acute Ischemic Stroke in Patients with Atrial Fibrillation. <i>Pharmacotherapy</i> , 2020, 40, 55-71.	1.2	14
639	Management of anticoagulated patients in dentoalveolar surgery: a clinical comparative study. <i>Clinical Oral Investigations</i> , 2020, 24, 2653-2662.	1.4	6
640	Mitral Valve Replacement With a Third-Generation Porcine Valve: An Italian Multicentered Study. <i>Annals of Thoracic Surgery</i> , 2020, 109, 1865-1872.	0.7	5
641	Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: A systematic review. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 533-547.	1.1	62
642	Validation of an algorithm to predict decline in INR following warfarin cessation in patients undergoing invasive procedures. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 630-635.	1.0	1
643	Simultaneous determination of Rivaroxaban and TAK-438 in rat plasma by LC-MS/MS: application to pharmacokinetic interaction study. <i>Bioanalysis</i> , 2020, 12, 11-22.	0.6	9
644	Recommendations of the Spanish Rheumatology Society for primary antiphospholipid syndrome. Part II: Obstetric antiphospholipid syndrome and special situations. <i>Reumatología Clínica (English Edition)</i> , 2020, 16, 133-148.	0.2	2
645	Current Strategies for the Management of Bleeding Associated with Direct Oral Anticoagulants and a Review of Investigational Reversal Agents. <i>Journal of Emergency Medicine</i> , 2020, 58, 217-233.	0.3	22
646	Prognostic impact of inappropriate doses of direct oral anticoagulants in clinical practice. <i>Revista Española De Cardiología (English Ed)</i> , 2020, 73, 329-330.	0.4	0
647	Timing to start anticoagulants after acute ischemic stroke with non-valvular atrial fibrillation. <i>Journal of the Neurological Sciences</i> , 2020, 409, 116582.	0.3	6
648	Perioperative Management of Direct Oral Anticoagulants in Intracranial Surgery. <i>Journal of Neurosurgical Anesthesiology</i> , 2020, 32, 300-306.	0.6	3
649	Comparative Effectiveness and Safety of Oral Anticoagulants Across Kidney Function in Patients With Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006515.	0.9	20
650	Emergent reversal of oral factor Xa inhibitors with four-factor prothrombin complex concentrate. <i>American Journal of Emergency Medicine</i> , 2020, 38, 2641-2645.	0.7	11
651	Prevention and Treatment of Bleeding with Direct Oral Anticoagulants. <i>Drugs</i> , 2020, 80, 1293-1308.	4.9	6

#	ARTICLE	IF	CITATIONS
652	Oral anticoagulants and risk of acute liver injury in patients with nonvalvular atrial fibrillation: a propensity-weighted nationwide cohort study. <i>Scientific Reports</i> , 2020, 10, 11624.	1.6	10
653	Trends in the Prescription of Non-Vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation: Results of the Polish Atrial Fibrillation (POL-AF) Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 3565.	1.0	5
654	The increased risk of bleeding due to drug-drug interactions in patients administered direct oral anticoagulants. <i>Thrombosis Research</i> , 2020, 195, 243-249.	0.8	20
655	Long term efficacy and safety of rivaroxaban plus cilostazol in the treatment of critical ischemia of the lower limbs in a frail, elderly patient with non valvular atrial fibrillation. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2020, 6, 17.	0.4	0
656	Arrhythmias and COVID-19. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 1193-1204.	1.3	117
657	Slightly elevated international normalized ratio predicts bleeding episodes in patients treated with direct oral anticoagulants. <i>Journal of International Medical Research</i> , 2020, 48, 030006051989443.	0.4	2
658	Outcomes and anticoagulation use for elderly patients that present with an acute hip fracture: multi-centre, retrospective analysis. <i>Internal Medicine Journal</i> , 2022, 52, 418-425.	0.5	6
659	Non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation: safety issues in the elderly. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1309-1327.	1.3	5
660	Drug interactions with apixaban: A systematic review of the literature and an analysis of Vigibase, the World Health Organization database of spontaneous safety reports. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00647.	1.1	21
661	Patients Taking Direct Oral Anticoagulants (DOAC) Undergoing Oral Surgery: A Review of the Literature and a Proposal of a Peri-Operative Management Protocol. <i>Healthcare (Switzerland)</i> , 2020, 8, 281.	1.0	8
662	Management of Outpatient Warfarin Therapy amid COVID-19 Pandemic: A Practical Guide. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 301-309.	1.0	24
663	Laboratory monitoring of rivaroxaban in Chinese patients with deep venous thrombosis: a preliminary study. <i>BMC Pharmacology & Toxicology</i> , 2020, 21, 38.	1.0	2
664	A review of guidelines on anticoagulation reversal across different clinical scenarios – Is there a general consensus?. <i>American Journal of Emergency Medicine</i> , 2020, 38, 1890-1903.	0.7	26
665	Impact of direct oral anticoagulant therapy on operative delay, blood loss, transfusion and postoperative morbidity mortality in hip fracture patient, an observational study. <i>Thrombosis Research</i> , 2020, 194, 165-167.	0.8	2
666	Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice. <i>Drugs</i> , 2020, 80, 1065-1083.	4.9	22
667	Anti-Factor Xa Activity of Standard and Japan-Specific Doses of Rivaroxaban in Thai Patients With Non-Valvular Atrial Fibrillation. <i>Circulation Journal</i> , 2020, 84, 1075-1082.	0.7	3
668	Anticoagulation in AF and Elderly Frail Patient: How to Face New Challenges. , 2020, , .		0
669	Development of an application for management of drug holidays in perioperative periods. <i>Medicine (United States)</i> , 2020, 99, e20142.	0.4	4

#	ARTICLE	IF	CITATIONS
671	Predictors of localization, outcome, and etiology of spontaneous intracerebral hemorrhages: focus on cerebral amyloid angiopathy. <i>Journal of Neural Transmission</i> , 2020, 127, 963-972.	1.4	10
673	Monitoring the roles of prothrombin activation fragment 1 and 2 (F1+2) in patients with atrial fibrillation receiving rivaroxaban and apixaban. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 371-379.	1.0	2
674	Durability of bioprosthetic aortic valves in patients under the age of 60 years – rationale and design of the international INDURE registry. <i>Journal of Cardiothoracic Surgery</i> , 2020, 15, 119.	0.4	18
675	Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats. <i>Pharmaceutical Biology</i> , 2020, 58, 630-635.	1.3	5
676	Direct-Acting Oral Anticoagulants Versus Warfarin in Medicare Patients With Chronic Kidney Disease and Atrial Fibrillation. <i>Stroke</i> , 2020, 51, 2364-2373.	1.0	33
677	Predictive ability of creatinine clearance versus estimated glomerular filtration rate for outcomes in patients with non-valvular atrial fibrillation: Subanalysis of the J-RHYTHM Registry. <i>IJC Heart and Vasculature</i> , 2020, 29, 100559.	0.6	4
678	Safety of Anticoagulation in Patients Treated With Urgent Reperfusion for Ischemic Stroke Related to Atrial Fibrillation. <i>Stroke</i> , 2020, 51, 2347-2354.	1.0	7
679	Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population-based nested case-control study. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1150-1164.	1.1	42
680	Anticoagulant-associated intracerebral hemorrhage. <i>Brain Hemorrhages</i> , 2020, 1, 89-94.	0.4	19
681	Differences in anticoagulation strategy and outcome in atrial fibrillation patients with chronic kidney disease: a CODE-AF registry study. <i>International Journal of Arrhythmia</i> , 2020, 21, .	0.3	1
682	Soluble ST2 is a Useful Biomarker for Grading Cerebral Cardiac Syndrome in Patients after Acute Ischemic Stroke. <i>Journal of Clinical Medicine</i> , 2020, 9, 489.	1.0	4
683	Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany – Updated series of 120 cases. <i>International Journal of Stroke</i> , 2020, 15, 609-618.	2.9	54
684	NOAC dosing and monitoring: really as simple as it seems?. <i>Heart</i> , 2020, 106, 321-322.	1.2	3
685	Diagnostic value of N-terminal pro B-type natriuretic peptide for nonvalvular atrial fibrillation in acute ischemic stroke patients: A retrospective multicenter case-control study. <i>Journal of the Neurological Sciences</i> , 2020, 414, 116822.	0.3	8
686	Interindividual Variability of Apixaban Plasma Concentrations: Influence of Clinical and Genetic Factors in a Real-Life Cohort of Atrial Fibrillation Patients. <i>Genes</i> , 2020, 11, 438.	1.0	17
687	Patient Knowledge about Oral Anticoagulation Therapy Assessed during an Intermediate Medication Review in Swiss Community Pharmacies. <i>Pharmacy (Basel, Switzerland)</i> , 2020, 8, 54.	0.6	8
688	Non-Vitamin K Oral Anticoagulants (NOAC) versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type. <i>Journal of Clinical Medicine</i> , 2020, 9, 1120.	1.0	26
689	Medical Management of Rheumatic Heart Disease. , 2021, , 107-132.		0

#	ARTICLE	IF	CITATIONS
690	Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants—a Swedish, register-based cohort study in atrial fibrillation outpatients. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 409-419.	0.8	19
691	Gastroprotection in patients on antiplatelet and/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO). <i>European Journal of Internal Medicine</i> , 2021, 85, 1-13.	1.0	31
692	Appropriateness of direct oral anticoagulant dosing in patients with atrial fibrillation according to the drug labelling and the EHRA Practical Guide. <i>International Journal of Cardiology</i> , 2021, 328, 97-103.	0.8	10
693	2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2021, 77, 629-658.	1.2	144
694	Anticoagulación oral en la enfermedad renal crónica con fibrilación auricular. <i>Nefrología</i> , 2021, 41, 137-153.	0.2	6
695	Outcomes Associated With 4-Factor Prothrombin Complex Concentrate Administration to Reverse Oral Factor Xa Inhibitors in Bleeding Patients. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 598-605.	1.0	5
696	Trends in anticoagulation management services following incorporation of direct oral anticoagulants at a large academic medical center. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 1050-1058.	1.0	2
697	Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021, 128, 297-304.	1.2	21
698	Cas particuliers. , 2021, , 79-93.		0
699	Oral Anticoagulant Therapy in the Arab World. , 2021, , 1-27.		0
701	Oral Anticoagulant Therapy in the Arab World. , 2021, , 2871-2896.		0
702	Development and clinical use of an application for management of drug holidays in perioperative periods. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2021, 32, 339-348.	0.1	1
703	Risk Stratification For and Use of DOAC Therapies for Stroke Prevention in Patient with Atrial Fibrillation. , 2021, , 93-119.		0
704	Early recurrent ischemic events after mechanical thrombectomy: effect of post-treatment intracranial hemorrhage. <i>Journal of Neurology</i> , 2021, 268, 2810-2820.	1.8	4
705	Effect of Rivaroxaban or Apixaban in Atrial Fibrillation Patients with Stage 4-5 Chronic Kidney Disease or on Dialysis. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 273-281.	1.3	19
706	Nonvitamin K oral anticoagulants in cardiac surgery: What cardiothoracic surgeons need to know 2.0. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, 2145-2152.	0.4	4
707	The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants. <i>Medicine (United States)</i> , 2021, 100, e25216.	0.4	10
708	Oral anticoagulation in chronic kidney disease with atrial fibrillation. <i>Nefrología</i> , 2021, 41, 137-153.	0.2	0

#	ARTICLE	IF	CITATIONS
710	Use of NOACS in high-risk patients with atrial fibrillation in Saudi Arabia: Perspectives on improving patient care. <i>Expert Review of Cardiovascular Therapy</i> , 2021, 19, 221-236.	0.6	2
711	Use of NOACS in high-risk patients with atrial fibrillation in Saudi Arabia: Perspectives on improving patient care. <i>Expert Review of Cardiovascular Therapy</i> , 2021, 19, 221-236.	0.6	2
712	Safe prescribing of direct oral anticoagulants for non-valvular AF. <i>The Prescriber</i> , 2021, 32, 26-30.	0.1	0
713	Anticoagulation treatment. <i>Medicine</i> , 2021, 49, 234-237.	0.2	0
714	Oral Anticoagulant Agents in Patients With Atrial Fibrillation and CKD: A Systematic Review and Pairwise Network Meta-analysis. <i>American Journal of Kidney Diseases</i> , 2021, 78, 678-689.e1.	2.1	24
715	Factor VIII Inhibitor Bypassing Activity (FEIBA) Reversal for Apixaban and Rivaroxaban in Patients With Acute Intracranial and Nonintracranial Hemorrhage. <i>Annals of Pharmacotherapy</i> , 2021, 55, 1455-1466.	0.9	3
716	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. <i>Europace</i> , 2021, 23, 1612-1676.	0.7	494
717	Unmet Clinical Needs in Elderly Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation. <i>Advances in Therapy</i> , 2021, 38, 2891-2907.	1.3	7
719	Completion Report of the Overseas Training Program Awarded by Japanese Society of Clinical Pharmacology and Therapeutics in 2019. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2021, 52, 95-97.	0.1	0
720	The development and validation of a multivariable model to predict the bleeding risk score for patients with non-valvular atrial fibrillation using direct oral anticoagulants in the Arab population. <i>PLoS ONE</i> , 2021, 16, e0250502.	1.1	4
721	Intracardiac thrombus in a patient with mitral bioprosthesis and atrial fibrillation treated with direct oral anticoagulant. <i>Medicine (United States)</i> , 2021, 100, e26137.	0.4	1
722	Long-Term Clinical Outcomes of Underdosed Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Atrial Flutter. <i>American Journal of Medicine</i> , 2021, 134, 788-796.	0.6	25
723	The importance of use of appropriate anticoagulant in atrial fibrillation after gastric bypass surgery. <i>HeartRhythm Case Reports</i> , 2021, 7, 354-356.	0.2	4
724	Preoperative Cardiovascular Assessment of the Renal Transplant Recipient: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 2525.	1.0	5
725	Orthogeriatric co-management for the care of older subjects with hip fracture: recommendations from an Italian intersociety consensus. <i>Aging Clinical and Experimental Research</i> , 2021, 33, 2405-2443.	1.4	11
726	Thromboembolism, Bleeding, and Mortality Incidence of Direct Oral Anticoagulants Versus Warfarin Postbariatric Surgery. <i>American Journal of Medicine</i> , 2021, 134, 1403-1412.e2.	0.6	4
727	Severe Bleeding Risk of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Stroke Prevention and Treatment in Patients with Atrial Fibrillation: A Systematic Review and Network Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 363-377.	1.3	7
728	Trauma-induced pulmonary thromboembolism: What's update?. <i>Chinese Journal of Traumatology - English Edition</i> , 2022, 25, 67-76.	0.7	7

#	ARTICLE	IF	CITATIONS
729	Safety and interaction of direct oral anticoagulants with antiarrhythmic drugs. Russian Journal of Cardiology, 2021, 26, 4482.	0.4	0
730	CKD Progression in Medicare Beneficiaries With Nonvalvular Atrial Fibrillation Treated With Apixaban Versus Warfarin. American Journal of Kidney Diseases, 2021, 78, 180-189.e1.	2.1	15
731	Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions. Expert Review of Hematology, 2021, 14, 819-830.	1.0	4
732	Direct (New) Oral Anticoagulants (DOACs): Drawbacks, Bleeding and Reversal. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2022, 20, 103-113.	0.4	9
733	A strategy for assessment and validation of major bleeding cases in a primary health care database in Spain. Pharmacoepidemiology and Drug Safety, 2021, 30, 1696-1702.	0.9	1
734	Experiencing a virtual patient to practice patient counselling skills. Currents in Pharmacy Teaching and Learning, 2021, 13, 1593-1601.	0.4	4
736	Comparison of the Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Cardiovascular Medicine, 2021, 8, 712585.	1.1	1
737	An Update of the Efficacy and Comparative Characteristics of Direct (New) Oral Anticoagulants (DOACs). Cardiovascular and Hematological Agents in Medicinal Chemistry, 2022, 20, 114-124.	0.4	2
738	Dentoalveolar Procedures in Immune Thrombocytopenia; Systematic Review and an Institutional Guideline. TH Open, 2021, 05, e489-e502.	0.7	1
739	Burden of major gastrointestinal bleeding among oral anticoagulant-treated non-valvular atrial fibrillation patients. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482199735.	1.4	19
740	Concurrent use of P-glycoprotein or Cytochrome 3A4 drugs and non-vitamin K antagonist oral anticoagulants in non-valvular atrial fibrillation. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 195-201.	1.8	5
742	Oral Manifestations of Systemic Diseases and their Treatments. , 2018, , 1-117.		4
743	Ischemic stroke and non-valvular atrial fibrillation: When to introduce anticoagulant therapy?. JMV-Journal De Medecine Vasculaire, 2020, 45, 72-80.	0.1	4
744	Chronic kidney disease and arrhythmias: highlights from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2018, 94, 231-234.	2.6	26
746	The effect of bariatric surgery on direct-acting oral anticoagulant drug levels. Thrombosis Research, 2018, 163, 190-195.	0.8	53
747	The patient pathway in cardiovascular care: A position paper from the International Pharmacists for Anticoagulation Care Taskforce (iPACT). Journal of Evaluation in Clinical Practice, 2020, 26, 670-681.	0.9	4
748	Cognitive function and adherence to anticoagulation treatment in patients with atrial fibrillation. Journal of Geriatric Cardiology, 2016, 13, 559-65.	0.2	32
749	Atrial fibrillation in the elderly. Journal of Geriatric Cardiology, 2019, 16, 49-53.	0.2	27

#	ARTICLE	IF	CITATIONS
750	JCS/JSCS/JATS/JSVS 2020 Guidelines on the Management of Valvular Heart Disease. <i>Circulation Journal</i> , 2020, 84, 2037-2119.	0.7	150
751	Dosing Accuracy of Direct Oral Anticoagulants in an Academic Medical Center. <i>Journal of Hospital Medicine</i> , 2017, 12, 544-550.	0.7	10
752	Risk of Ischemic Stroke, Hemorrhagic Stroke, Bleeding, and Death in Patients Switching from Vitamin K Antagonist to Dabigatran after an Ablation. <i>PLoS ONE</i> , 2016, 11, e0161768.	1.1	2
753	ReAl-life Multicenter Survey Evaluating Stroke prevention strategies in non-valvular atrial fibrillation (RAMSES study). <i>Anatolian Journal of Cardiology</i> , 2016, 16, 734-741.	0.5	17
754	Management of Complications in Anticoagulated Patients with Atrial Fibrillation. <i>Arrhythmia and Electrophysiology Review</i> , 2017, 6, 167.	1.3	1
755	Practical Implementation of Anticoagulation Strategy for Patients Undergoing Cardioversion of Atrial Fibrillation. <i>Arrhythmia and Electrophysiology Review</i> , 2017, 6, 50.	1.3	7
756	Perioperative management of patients receiving non-vitamin K antagonist oral anticoagulants: up-to-date recommendations. <i>Anesthesia and Pain Medicine</i> , 2020, 15, 133-142.	0.5	5
757	Atrial Fibrillation and Stroke in Elderly Patients. <i>Journal of Patient-centered Research and Reviews</i> , 2016, 3, 217-229.	0.6	5
760	Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. <i>Annals of Translational Medicine</i> , 2017, 5, 465-465.	0.7	3
761	Novel Perspective for Antithrombotic Therapy in TAVI. <i>Current Pharmaceutical Design</i> , 2020, 26, 2789-2803.	0.9	2
762	The Role of Antithrombotic Therapy in Heart Failure. <i>Current Pharmaceutical Design</i> , 2020, 26, 2735-2761.	0.9	1
763	The Health Buddies App as a Novel Tool to Improve Adherence and Knowledge in Atrial Fibrillation Patients: A Pilot Study. <i>JMIR MHealth and UHealth</i> , 2017, 5, e98.	1.8	43
764	Clinical standards for patient blood management and perioperative hemostasis and coagulation management. Position Paper of the Italian Society of Anesthesia, Analgesia, Resuscitation and Intensive Care (SIAARTI). <i>Minerva Anestesiologica</i> , 2019, 85, 635-664.	0.6	14
765	CHRONIC KIDNEY DISEASE AND ARRHYTHMIAS: CONCLUSIONS FROM A KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES (KDIGO) CONTROVERSIES CONFERENCE. <i>Nephrology (Saint-Petersburg)</i> , 2019, 23, 18-40.	0.1	5
766	Patterns of anticoagulation therapy in atrial fibrillation: results from a large real-life single-center registry. <i>Croatian Medical Journal</i> , 2020, 61, 440-449.	0.2	5
767	Non-vitamin k antagonist oral anticoagulants in a European primary care physician survey. <i>BJGP Open</i> , 2018, 2, bjgpopen18X101602.	0.9	4
768	DOACs vs Vitamin K Antagonists: a Comparison of Phase III Clinical Trials and a Prescriber Support Tool. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2019, 7, 1226-1232.	0.1	10
769	Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation. <i>Korean Journal of Medicine</i> , 2016, 90, 189-197.	0.1	4

#	ARTICLE	IF	CITATIONS
770	2018 KHRS Expert Consensus Recommendation for Oral Anticoagulants Choice and Appropriate Doses: Specific Situation and High Risk Patients. Korean Journal of Medicine, 2018, 93, 110-132.	0.1	6
771	2018 KHRS Guidelines for Stroke Prevention Therapy in Korean Patients with Nonvalvular Atrial Fibrillation. Korean Journal of Medicine, 2018, 93, 87-109.	0.1	8
773	The 2018 Korean Heart Rhythm Society Practical Guidelines on the use of Non-Vitamin K-Antagonist Oral Anticoagulants: Bleeding Control and Perioperative Management. Korean Journal of Medicine, 2019, 94, 40-56.	0.1	7
774	Apixaban-Induced Resolution of A Massive Left Atrial and Appendage Thrombosis in a Very Elderly Patient. Journal of Atrial Fibrillation, 2016, 9, 1509.	0.5	3
775	Critical Issues and Recent Advances in Anticoagulant Therapy: A Review. Neurology India, 2019, 67, 1200.	0.2	4
776	New indications for dabigatran: A suggestion from a drug use evaluation study. Journal of Research in Pharmacy Practice, 2017, 6, 211.	0.2	4
777	Direct oral anticoagulants: a guide for daily practice. Swiss Medical Weekly, 2016, 146, w14286.	0.8	11
778	Risk of left atrial appendage thrombus in patients with atrial fibrillation and chronic kidney disease. Cardiology Journal, 2022, 29, 205-215.	0.5	7
779	Non-Vitamin K Oral Anticoagulants in Stroke Patients: Practical Issues. Journal of Stroke, 2016, 18, 138-145.	1.4	13
780	Non-Vitamin K Oral Anticoagulants in Stroke Patients: Practical Issues. Journal of Stroke, 2017, 19, 104-106.	1.4	4
781	Apixaban. American Journal of Therapeutics, 2021, Publish Ahead of Print, e212-e218.	0.5	0
782	Why Did All Patients with Atrial Fibrillation and High Risk of Stroke Not Receive Oral Anticoagulants? Results of the Polish Atrial Fibrillation (POL-AF) Registry. Journal of Clinical Medicine, 2021, 10, 4611.	1.0	1
783	Overview of Acute Ischemic Stroke Evaluation and Management. Biomedicines, 2021, 9, 1486.	1.4	25
784	A prospective comparative study to assess the risk of postoperative bleeding after dental surgery while on medication with direct oral anticoagulants, antiplatelet agents, or vitamin K antagonists. BMC Oral Health, 2021, 21, 504.	0.8	4
785	Stroke Prevention in Atrial Fibrillation – The Use of NOACs in Everyday Clinical Practice. European Cardiology Review, 2015, 10, 76.	0.7	1
787	Management of atrial fibrillation in specific patient populations. Kardiologia Polska, 2016, 74, 1-8.	0.3	2
789	Use of NOAC in Cardioversion. International Journal of Arrhythmia, 2016, 17, 46-50.	0.3	0
790	NOAC for Patients with AF and ACS. International Journal of Arrhythmia, 2016, 17, 41-45.	0.3	0

#	ARTICLE	IF	CITATIONS
791	Peri-procedural Management of Anticoagulation Therapy (cataract eye surgery, dental procedure and) Tj ETQq0 0 0,rgBT /Overlock 10 T	0.3	0
792	Beyond warfarin: The advent of new oral anticoagulants. Indian Journal of Radiology and Imaging, 2016, 26, 419-420.	0.3	0
793	Stroke Treatment: Current News and Developments. Turk Noroloji Dergisi = Turkish Journal of Neurology, 2016, 22, 145-147.	0.1	0
795	Sinus Conversion of Atrial Fibrillation by Restoration of Atrial Perfusion in a Patient with Chronic Total Occlusion. International Journal of Arrhythmia, 2016, 17, 158-162.	0.3	1
796	Electrophysiology Updates in Adult Congenital Heart Disease. Texas Heart Institute Journal, 2016, 43, 409-411.	0.1	0
797	Management of Oral Anti-Thrombotic Agents Associated Intracerebral Hemorrhage. Journal of Neurocritical Care, 2016, 9, 113-124.	0.4	0
798	Atrial Fibrillation on Non-vitamin K Antagonist Oral Anticoagulant Undergoing Elective Percutaneous Coronary Intervention for Stable Effort Angina. , 2017, , 19-38.		0
799	New-Onset Atrial Fibrillation in a Stable Patient with Remote Percutaneous Coronary Intervention. , 2017, , 141-152.		0
800	Kardiologie. , 2017, , 203-314.		0
801	Major Bleeding Early After Percutaneous Coronary Intervention in a Patient with Atrial Fibrillation on Triple Therapy with a Non-vitamin K-Antagonist Oral Anticoagulant, Aspirin, and Clopidogrel. , 2017, , 197-212.		0
802	Atrial Fibrillation on Vitamin K Antagonist Oral Anticoagulant Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Acute Myocardial Infarction. , 2017, , 95-120.		0
803	Urgent Surgery Early After Percutaneous Coronary Intervention in a Patient with Atrial Fibrillation on Triple Therapy of Non-vitamin K Antagonist Oral Anticoagulant, Aspirin, and Clopidogrel. , 2017, , 169-182.		0
804	Atrial Fibrillation on Vitamin K Antagonist Undergoing Urgent Percutaneous Coronary Intervention for Non-ST-Elevation Acute Coronary Syndrome. , 2017, , 39-58.		0
805	Atrial Fibrillation Early Complicating Acute Coronary Syndrome Treated with Percutaneous Coronary Intervention. , 2017, , 121-140.		0
806	Ritmestoornissen. , 2017, , 75-162.		0
807	Atrial Fibrillation in the Elderly. , 2017, , 149-163.		0
808	Medikamentöse und operative Sekundärprophylaxe. Fachwissen Pflege, 2017, , 93-105.	0.0	0
809	Leitsymptom Herzrasen. , 2017, , 69-113.		0

#	ARTICLE	IF	CITATIONS
810	Kardialer Check-up. , 2017, , 311-350.		0
811	Concerns with Anticoagulant Adherence. , 2017, , 37-42.		0
812	Patient Presenting with Major, Life-Threatening Bleeding. , 2017, , 289-294.		0
813	Patient with Concomitant Stable Coronary Artery Disease. , 2017, , 69-73.		0
814	6. Anticoagulant Therapy. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 238-245.	0.0	0
815	Multiple Intracranial Hemorrhage Following Intravenous Recombinant Plasminogen Activator in the Patients Taking Rivaroxaban. Journal of the Korean Neurological Association, 2017, 35, 50-52.	0.0	0
816	Peri-operative care of patients with antikoagulation therapy. Intervencni A Akutni Kardiologie, 2017, 16, 18-22.	0.0	0
819	Atrial Fibrillation in Patients with Cardiac Resynchronization Therapy: Therapeutic Options. Cardiologia Croatica, 2017, 12, 254-263.	0.0	1
820	Rivaroxaban in high-risk patients. Vnitri Lekarstvi, 2017, 63, 424-430.	0.1	2
821	Diagnosis, prevention and treatment of chronic heart failure: what the therapist of the outpatient health care unit should know (according to the recommendations of the European Society of) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T Cardiosomatics. 2017, 8, 29-38.	0.2	0
822	Medication adherence to non-vitamin K antagonist oral anticoagulants at non-valvular atrial fibrillation - the literature review. Vnitri Lekarstvi, 2017, 63, 633-639.	0.1	2
823	Early Anticoagulation for Recurrent Ischemic Stroke despite the Presence of Ventricular Bleeding. Journal of Neurology & Stroke, 2017, 7, .	0.0	0
824	Problems of anticoagulant therapy in elderly cancer patients with atrial fibrillation and hemorrhagic stroke. OnCORReview, 2017, 7, 168-170.	0.1	0
826	Clinical Manual for Diagnosis, Prevention and Treatment of Cardiovascular Complications of Cancer Therapy. Parts II-V. Systemic Hypertension, 2017, 14, 6-19.	0.1	2
827	2018 EHRA Practical Guide, Rationale, History and Experience. European Journal of Arrhythmia & Electrophysiology, 2018, 4, 43.	0.2	0
829	Reversal Agents: What We Have and What We Can Expect. Journal of Innovations in Cardiac Rhythm Management, 2018, 9, 3108-3114.	0.2	2
830	Periprocedural management of patients on anticoagulants and antiplatelet agents undergoing cardiac implantable electronic device implantation. In A Good Rythm, 2018, 1, 17-23.	0.0	0
832	4. Efficasy and Safety of DOAC Versus Warfarin in Chronic Kidney Disease. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 856-864.	0.0	0

#	ARTICLE	IF	CITATIONS
833	Hemorragia grave en el paciente anticoagulado. Medicina Clínica, 2018, 150, 30-37.	0.3	0
835	ASSESSMENT OF ANTICOAGULANT DRUGS IN ELIGIBLE PATIENTS WITH ATRIAL FIBRILLATION. Journal of Sulaimani Medical College, 2018, 8, 199-204.	0.0	0
836	AVALIAÇÃO DA SEGURANÇA DOS NOVOS ANTICOAGULANTES ORAIS (NOACS) NO PERIOPERATÓRIO DE CIRURGIAS ELETIVAS: UMA REVISÃO DA LITERATURA. , 0, , .		0
837	A critical analysis of antithrombotic strategy in the acute period of ischemic stroke. Klinicheskaia Meditsina, 2018, 96, 773-783.	0.2	0
838	Recent Advances for Stroke Prevention in Patients With Atrial Fibrillation and Advanced Kidney Disease. , 2019, , 736-740.e2.		0
839	Perioperative management of patients receiving long-term antithrombotic therapy. Russian Federation of anesthesiologists and reanimatologists guidelines. Alexander Saltanov Intensive Care Herald, 2019, , 7-19.	0.2	8
840	CHOICE OF DIRECT ORAL ANTICOAGULANTS BASED ON THE INDIVIDUAL APPROACH. Translational Medicine, 2019, 5, 10-22.	0.1	0
842	Application of a new peroral anticoagulants in treatment and prophylaxis of thromboembolic complications. Klinichna Khirurgiia, 2019, 86, 73-76.	0.0	1
843	Treatment of patients with acute coronary syndrome and atrial fibrillation. ScienceRise: Medical Science, 2019, .	0.0	0
844	Possible timing for anticoagulation therapy initiation in ischemic stroke patients with atrial fibrillation: further analysis of the hemorrhagic transformation index. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2019, 11, 12-21.	0.2	4
845	Manejo práctico de los nuevos anticoagulantes orales en fibrilación auricular no valvular. Medunab, 2019, 22, 38-50.	0.0	0
846	Consensus Report on Patient Blood Management in Cardiac Surgery by Turkish Society of Cardiovascular Surgery (TSCVS), Turkish Society of Cardiology (TSC), and Society of Cardio-Vascular-Thoracic Anaesthesia and Intensive Care (SCTAIC). Turkish Journal of Thoracic and Cardiovascular Surgery, 2019, 27, 429-450.	0.2	4
847	Long-Term Outcome of Acute Coronary Syndromes in Patients on Chronic Oral Anticoagulants: Data from the EPICOR Study. Current Vascular Pharmacology, 2019, 18, 92-99.	0.8	0
848	Results of Therapy Using Oral Anticoagulants in the Acute Phase after Mechanical Thrombectomy. Journal of Neuroendovascular Therapy, 2020, 14, 481-487.	0.1	0
849	Leitsymptom Herzrasen. , 2020, , 73-116.		0
850	Practical issues in measuring the anticoagulant effect of direct oral anticoagulants. Arhiv Za Farmaciju, 2020, 70, 297-309.	0.2	0
851	Incidence Rates of Bleeding and Emergency Surgery Due to Trauma or Fracture Among Japanese Patients with Non-valvular Atrial Fibrillation Receiving Oral Anticoagulation Therapy. Cardiology and Therapy, 2020, 9, 189-199.	1.1	4
852	Antithrombotic therapy after percutaneous and surgical interventions on valves. Intervencni A Akutni Kardiologie, 2020, 19, 48-52.	0.0	0

#	ARTICLE	IF	CITATIONS
853	Thoracoscopic surgical ablation versus catheter ablation as first-line treatment for long-standing persistent atrial fibrillation: the CASA-AF RCT. Efficacy and Mechanism Evaluation, 2021, 8, 1-122.	0.9	2
854	Safety and Effectiveness of Rivaroxaban in Combination with Various Antiarrhythmic Drugs in Patients with Non-Permanent Atrial Fibrillation. American Journal of Cardiovascular Drugs, 2021, 21, 459-469.	1.0	7
855	Kardialer Check-up. , 2020, , 313-347.		0
856	The prevalence of acute erosive-ulcerative gastroduodenal lesions in patients with cardiovascular diseases, taking anticoagulants and antiplatelet agents. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2020, , 65-74.	0.1	1
858	Heterogeneity in Preferences for Anti-coagulant Use in Atrial Fibrillation: A Latent Class Analysis. Patient, 2020, 13, 445-455.	1.1	0
859	Thromboembolic disease: a geriatric syndrome. Journal of Gerontology and Geriatrics, 2021, 69, 68-78.	0.2	0
861	Non-Vitamin K Antagonist Oral Anticoagulants and Factors Influencing the Ischemic and Bleeding Risk in Elderly Patients With Atrial Fibrillation: A Review of Current Evidence. Journal of Cardiovascular Pharmacology, 2021, 77, 11-21.	0.8	6
862	Novel Oral Anticoagulants in Renal Transplant Recipients: A Retrospective Cohort Study. Prilozi - Makedonska Akademija Na Naukite I Umetnostite Oddelenie Za Medicinski Nauki, 2020, 41, 49-55.	0.2	2
863	Exploring indications for the Use of direct oral anticoagulants and the associated risks of major bleeding. American Journal of Managed Care, 2017, 23, S67-S80.	0.8	18
864	Testing direct oral anticoagulants: embedding in structured long-term care. Blood Transfusion, 2018, 16, 410-412.	0.3	1
865	Reducing upper digestive bleeding risk in patients treated with direct oral anticoagulants and concomitant infection with. Experimental and Therapeutic Medicine, 2020, 20, 205.	0.8	1
866	Atrial fibrillation in patients with systolic heart failure: pathophysiology mechanisms and management. Journal of Geriatric Cardiology, 2021, 18, 376-397.	0.2	1
867	Reversal of anticoagulation in neurosurgical and neurocritical care settings. , 2022, , 239-266.		0
868	Anti-Xa Levels in Morbidly Obese Patients Using Apixaban or Rivaroxaban, Before and After Bariatric Surgery. Obesity Surgery, 2022, 32, 607-614.	1.1	7
869	Long-term adherence to direct acting oral anticoagulants and the influence of health beliefs after switching from vitamin-K antagonists: Findings from the Switching Study. Thrombosis Research, 2021, 208, 162-169.	0.8	5
870	Progress in the Use of Anticoagulant Drugs in Elderly Patients. Advances in Clinical Medicine, 2021, 11, 5911-5916.	0.0	0
871	Reducing upper digestive bleeding risk in patients treated with direct oral anticoagulants and concomitant infection with Helicobacter pylori. Experimental and Therapeutic Medicine, 2020, 20, 1-1.	0.8	6
872	ANTICOAGULANT AND ANTIPLATELET THERAPY OVER PERIOPERATIVE PERIOD. Pain Anesthesia and Intensive Care, 2021, , 65-77.	0.1	5

#	ARTICLE	IF	CITATIONS
873	Oral anticoagulant treatment after bioprosthetic valvular intervention or valvuloplasty in patients with atrial fibrillation—A SWEDHEART study. PLoS ONE, 2022, 17, e0262580.	1.1	4
874	Three-year clinical interventions from an outpatient multidisciplinary direct oral anticoagulant monitoring service. JACCP Journal of the American College of Clinical Pharmacy, 0, , .	0.5	1
875	Healthcare Resource Utilization for Oral Anticoagulant Reversal Therapies in Non-Valvular Atrial Fibrillation/Venous Thromboembolism Patients. Cardiology Research, 2022, 13, 27-43.	0.5	2
876	Implementing an electronic health record dashboard for safe anticoagulant management: learning from qualitative interviews with existing and potential users to develop an implementation process. Implementation Science Communications, 2022, 3, 10.	0.8	10
877	Kardialer Check-up. , 2022, , 329-369.		0
878	Novel Anticoagulants and Hip Fractures in the Elderly. Cureus, 2022, 14, e23020.	0.2	0
879	The effect of contrast agents on the anticoagulant properties of oral factor Xa inhibitors. Acta Radiologica, 2022, , 028418512210814.	0.5	0
880	Changes in the Gut Microbiota May Affect the Clinical Efficacy of Oral Anticoagulants. Frontiers in Pharmacology, 2022, 13, 860237.	1.6	6
881	Intracranial hemorrhage associated with direct oral anticoagulant after clipping for an unruptured cerebral aneurysm: A report of two cases. , 2022, 13, 104.		1
882	Switching from warfarin to direct-acting oral anticoagulants: it is time to move forward!. Egyptian Heart Journal, 2022, 74, 18.	0.4	3
884	The profile of patients with atrial fibrillation scheduled for cardioversion or catheter ablation hospitalized in a Romanian rehabilitation hospital. Balneo and PRM Research Journal, 2021, , 306-313.	0.1	0
885	The impact on renal function after long-term use of anticoagulants in atrial fibrillation patients. Thrombosis Journal, 2021, 19, 98.	0.9	7
889	Challenging issues in the management of cancer-associated venous thromboembolism. Blood Research, 2022, 57, S44-S48.	0.5	1
890	Evaluation of a Clinical Decision Support System for the most evidence-based approach to managing perioperative anticoagulation. Journal of Clinical Anesthesia, 2022, 80, 110877.	0.7	2
891	Views, experiences and contributory factors related to medication errors associated with direct oral anticoagulants: a qualitative study with physicians and nurses. International Journal of Clinical Pharmacy, 2022, 44, 1057-1066.	1.0	6
892	Drug-Related Problems and Factors Involved in the Imbalance of Oral Anticoagulants in Lebanese Patients: A Cross-Sectional Study. Dr Sulaiman Al Habib Medical Journal, 2022, 4, 77-85.	0.3	0
893	An Updated Meta-Analysis of DOACs vs. VKAs in Atrial Fibrillation Patients With Bioprosthetic Heart Valve. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	3
894	Left Atrial Appendage Occlusion: Current Stroke Prevention Strategies and a Shift Toward Data-Driven, Patient-Specific Approaches. , 2022, 1, 100405.		2

#	ARTICLE	IF	CITATIONS
895	Core shell stationary phase for a novel separation of some COVID-19 used drugs by UPLC-MS/MS Method: Study of grapefruit consumption impact on their pharmacokinetics in rats. Microchemical Journal, 2022, 181, 107769.	2.3	0
896	Personalizing Direct Oral Anticoagulant Therapy for a Diverse Population: Role of Race, Kidney Function, Drug Interactions, and Pharmacogenetics. Clinical Pharmacology and Therapeutics, 2023, 113, 585-599.	2.3	4
898	Do Apixaban Plasma Levels Relate to Bleeding? The Clinical Outcomes and Predictive Factors for Bleeding in Patients with Non-Valvular Atrial Fibrillation. Biomedicines, 2022, 10, 2001.	1.4	4
899	Right selection of oral anticoagulation for stroke prevention in atrial fibrillation. Indian Journal of Pharmacy and Pharmacology, 2022, 9, 164-170.	0.1	0
900	Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week. European Heart Journal, 2022, 43, 3512-3527.	1.0	16
901	Outcomes in patients undergoing periprocedural interruption of warfarin or direct oral anticoagulants. Journal of Thrombosis and Haemostasis, 2022, 20, 2571-2578.	1.9	3
902	Safety and efficacy of the Amplatzer Amulet and Watchman 2.5 for left atrial appendage occlusion: A systematic review and meta-analysis. PACE - Pacing and Clinical Electrophysiology, 2022, 45, 1237-1247.	0.5	5
903	Appropriateness of Non-vitamin K Antagonist Oral Anticoagulants Dosing According to Different Prescription Guides Used in Belgian Ambulatory Care. Clinical Drug Investigation, 2022, 42, 775-786.	1.1	2
904	Twice- or once-daily dosing of direct oral anticoagulants and gastrointestinal bleeding in patient with atrial fibrillation. American Heart Journal Plus, 2022, 22, 100203.	0.3	1
905	Bleeding events in the emergency department with warfarin versus novel oral anticoagulants: A five-year analysis. Nigerian Journal of Clinical Practice, 2022, 25, 1308.	0.2	0
906	Bleeding events among patients concomitantly treated with direct oral anticoagulants and macrolide or fluoroquinolone antibiotics. British Journal of Clinical Pharmacology, 0, .	1.1	1
907	Impact of Renal Function on Anti-factor Xa Activity Concentrations with Edoxaban Use in Patients with Non-valvular Atrial Fibrillation. Drugs in R and D, 2022, 22, 281-288.	1.1	2
908	Prevention, Diagnosis and Treatment of Thromboembolic Complications in Traumatology and Orthopedics: Methodological Guidelines. Travmatologiya I Ortopediya Rossii, 2022, 28, 136-166.	0.1	5
909	Trends in direct oral anticoagulant (DOAC) prescribing in English primary care (2014-2019). Heart, 2023, 109, 195-201.	1.2	7
910	Cardiorenal Outcomes Among Patients With Atrial Fibrillation Treated With Oral Anticoagulants. American Journal of Kidney Diseases, 2023, 81, 307-317.e1.	2.1	10
911	EURASIAN CLINICAL RECOMMENDATIONS ON DIAGNOSIS AND TREATMENT OF ATRIAL FIBRILLATION. Eurasian Heart Journal, 2019, , 4-85.	0.2	13
912	N-terminal pro-B-type natriuretic peptide and D-dimer combined with left atrial diameter to predict the risk of ischemic stroke in nonvalvular atrial fibrillation. Clinical Cardiology, 2023, 46, 41-48.	0.7	6
913	Influence of ABCB1, CYP3A5 and CYP3A4 gene polymorphisms on prothrombin time and the residual equilibrium concentration of rivaroxaban in patients with non-valvular atrial fibrillation in real clinical practice. Pharmacogenetics and Genomics, 2022, 32, 301-307.	0.7	4

#	ARTICLE	IF	CITATIONS
914	Patient Blood Management in Vascular Surgery. <i>Anesthesiology Clinics</i> , 2022, 40, 605-625.	0.6	1
915	<scp>CytoSorb</scp> haemoadsorption for removal of apixabanâ€”A proofâ€”ofâ€”concept pilot case for a randomized controlled trial. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 2373-2375.	0.7	2
916	Safety and efficacy of direct oral anticoagulants in geriatric patients with non-valvular atrial fibrillation: A single-center retrospective study. <i>Thrombosis Research</i> , 2023, 221, 149-156.	0.8	1
917	Interpreting Findings with Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation: Collective Views on Data from Seminal Studies to Present in Clinical Practice. <i>EMJ Cardiology</i> , 0, , 34-41.	0.0	0
918	Minimisation of Bleeding Risks Due to Direct Oral Anticoagulants. <i>European Medical Journal Hematology</i> , 0, , 78-90.	0.0	0
919	Prinzipien der medikamentÃ¶sen Thromboembolieprophylaxe. <i>Springer Reference Medizin</i> , 2023, , 1-5.	0.0	0
920	Predicting Atrial Fibrillation after Ischemic Stroke: Clinical, Genetics, and Electrocardiogram Modelling. <i>Cerebrovascular Diseases Extra</i> , 2023, 13, 9-17.	0.5	2
921	Stroke Prevention with Anticoagulant in Cardiovascular Problem: Focus in Atrial Fibrillation. , 2023, , 269-292.		0
922	Pharmacist management of atrial fibrillation in UK primary care: a qualitative study. <i>Journal of Pharmaceutical Policy and Practice</i> , 2022, 15, .	1.1	1
923	Genetic variations in relation to bleeding and pharmacodynamics of dabigatran in Chinese patients with nonvalvular atrial fibrillation: A nationwide multicentre prospective cohort study. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	0
924	Efficacy and Safety of Renal Function on Edoxaban Versus Warfarin for Atrial Fibrillation: A Systematic Review and Meta-Analysis. <i>Medicines (Basel, Switzerland)</i> , 2023, 10, 13.	0.7	2
925	New score for predicting major bleeding in patients with atrial fibrillation using direct oral anticoagulants. <i>International Journal of Cardiology</i> , 2023, 376, 56-61.	0.8	1
926	A Cardiologistsâ€™ Survey on the Use of Anticoagulants and Antiplatelets in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Those Undergoing Percutaneous Coronary Intervention in India. <i>Cureus</i> , 2023, , .	0.2	0
927	To Measure or Not to Measure: Direct Oral Anticoagulant Laboratory Assay Monitoring in Clinical Practice. <i>Advances in Hematology</i> , 2023, 2023, 1-7.	0.6	0
928	Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care. <i>European Journal of Anaesthesiology</i> , 2023, 40, 226-304.	0.7	61
929	Nonvalvular atrial fibrillation in patients undergoing chronic hemodialysis. Should dialysis patients with atrial fibrillation receive oral anticoagulation?. <i>Nefrologia</i> , 2022, 42, 633-644.	0.2	0
930	Occurrence of Ischemic Stroke in Patients With Atrial Fibrillation Receiving Non-Vitamin K Oral Anticoagulants: Causes and Prevention Strategies. <i>Journal of Stroke</i> , 2023, 25, 199-213.	1.4	4
931	Challenges of Anticoagulant Therapy in Atrial Fibrillationâ€”Focus on Gastrointestinal Bleeding. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6879.	1.8	4

#	ARTICLE	IF	CITATIONS
942	Potentially inappropriate prescribing in multimorbid and polymedicated older adults with AF: A Systematic Review and Meta-Analysis. <i>Drugs and Aging</i> , 0, , .	1.3	0
943	Nicht Vitamin-K-abhÄngige orale Antikoagulanzen (NOAK). <i>Springer Reference Medizin</i> , 2023, , 1-8.	0.0	0
947	Development of a Perioperative Medication Suspension Decision Algorithm Based on Bayesian Networks. , 2024, , .		0